Member Press Releases

December 28, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced that Protiva Biotherapeutics Inc. (“Protiva”) issued a press release yesterday stating that it has filed a dismissal of its pending claims against INEX in the Superior Court of the State of California. Protiva also disclosed that it reserves the right to reinstate its claims against INEX in the future.

December 22, 2006
Vancouver, British Columbia, December 22, 2006 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today that it has closed a second tranche of its previously announced private placement. An additional 1,750,000 units were placed with new institutional and retail investors at a price of $0.50 per unit for total gross proceeds of $875,000.

December 22, 2006
VANCOUVER, Dec. 22 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that its wholly-owned subsidiary, QLT USA, Inc., has completed the sale of QLT USA's generic dermatology and manufacturing business located in Fort Collins, Colorado to Tolmar Inc., a private pharmaceutical company.

December 21, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has received notice that Protiva Biotherapeutics Inc. ( "Protiva") will appeal the decision of the Supreme Court of British Columbia approving the INEX Plan of Arrangement to transfer all of the Company’s transferable assets and liabilities to a spin-out Company, Tekmira Pharmaceuticals Corporation ("Tekmira"). The Supreme Court of British Columbia approved the Plan of Arrangement on November 24, 2006.

December 21, 2006
CARLSBAD, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that iCo Therapeutics, an Isis licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007, for the treatment of eye diseases including age-related macular degeneration (AMD) and diabetic retinopathy (DR). Isis will receive a milestone payment from iCo based on this IND filing.

December 21, 2006
VANCOUVER, Canada | Dec 21, 2006 | Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, is pleased to announce results of clinical trials of its hematological drug candidate, CTCE-0214.

December 19, 2006
Vancouver, December 19, 2006 - BC Advantage Funds (VCC) Ltd. ("Advantage") announced today that it is experiencing strong demand for its venture fund shares in advance of the upcoming tax selling season. Advantage has now sold over $5 million of its $10 million 2006 tax credit allocation and expects sales to continue to accelerate in late December and January. These tax credits provide Advantage investors with a 30% refundable tax credit for the 2006 taxation year (maximum $200,000 investment and $60,000 annual tax credit).

December 19, 2006
VANCOUVER, Dec. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) announced today that it has entered into a two-year research collaboration and option agreement with the Wilmer Eye Institute at Johns Hopkins University to research and develop potential treatments for dry age-related macular degeneration (AMD).

December 18, 2006

December 18, 2006
SANTA CRUZ, CALIFORNIA--(CCNMatthews - Dec. 18, 2006) - Technology Vision Group LLC (TVG) is pleased to announce program details for the 5th Annual BioPartnering North America (BPN: http://www.techvision.com/bpn) conference which will be held in Vancouver, B.C., Canada on February 4-6, 2007 as a partnership between TVG, BC Biotech, BioAlberta, and BIOTECanada. One of the hallmarks of BPN, and reasons for its continued success, is its innovative and informative program which features some of the hottest themes in the biotech industry today.

December 14, 2006

December 14, 2006
BURNABY, BC, Dec. 14 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI) is pleased to report on its Phase I Clinical Trial Schedule and progress.

December 13, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced today that a press conference will be held today in Paris, France to discuss Reducol™-based products and their application for a significant cholesterol problem in France. According to a recent survey of 1000 consumers conducted by Opinion Way Institute of France, sixty-three percent cited cardiovascular disease as being the number one cause of mortality in France.

December 12, 2006
Vancouver, December 12, 2006 - BC Advantage Funds (VCC) Ltd. announced today that Dr. Basil Peters has completed his engagement as Fund Manager of the BC Tech Fund - Advantage's early stage technology fund - and will not renew his contract.

December 11, 2006
VANCOUVER, Dec. 11 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), today announced that it has closed the previously announced sale of US $325 million in aggregate principal amount of its senior floating rate notes due 2013 in a private placement. The notes bear interest at an annual rate of LIBOR plus 3.75% and rank equally in right of payment to all of the company's existing and future senior indebtedness.

December 11, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) today presented pre-clinical data confirming earlier studies that its proprietary lead product candidate INX-0167 provides a strong immune response that translates into a dramatic enhancement in the anti-tumor activity of the monoclonal antibodies Rituxan® or Herceptin®.

December 8, 2006
Vancouver, BC – (December 8, 2006) –WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is pleased to announce the official grant to the Company of patent ZL 00124517.1 by the State Intellectual Property Office of the People’s Republic of China (SIPO) under the title of "Use of Tetrodotoxin and Saxitoxin and Their Analogs in Manufacturing Analgesic Drugs for Systemic Analgesia".

December 7, 2006
VANCOUVER, Canada, Dec. 7 /CNW/ -- Xenon today announced a partnership with Roche to discover and develop protein therapeutics targeting hemojuvelin (HJV) as a novel approach for the treatment of anemia of inflammation. Xenon discovered HJV as the defective protein underlying Juvenile Hemochromatosis and this protein appears to play an important role in the regulation and availability of iron for red blood cell production.

December 7, 2006
VANCOUVER, Dec. 7 /CNW/ - ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM:
OBP) (the "Company") is pleased to announce that it has issued an additional 462,500 common shares of the Company at a price of $1.60 per share for gross proceeds to the Company of $740,000 to an underwriting group led by Canaccord Capital Corporation and including Desjardins Securities Inc. and Pacific International Securities Inc. (collectively, the "Underwriters").

December 7, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, presented a case study during IBC’s EuroTIDES 2006 conference: Oligonucleotide, RNAi and Peptides for the Drug Development and Manufacturing Industry in Hamburg, Germany.

December 7, 2006
Vancouver, BC, Canada, December 7, 2006 – PACGEN Biopharmaceuticals Corporation (TSX-V – “PGA”) (“PACGEN”) announced today that it has completed an initial closing of 6,788,786 units raising gross proceeds of $7,128,225 under its prospectus dated November 28, 2006. Each unit is comprised of one common share in the capital of Pacgen and one-half of one non-transferable common share purchase warrant, with each whole warrant entitling the holder to purchase one additional common share at an exercise price of $1.30 for 12 months from the date of the closing.

December 7, 2006
Vancouver, BC – (December 7, 2006) –WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announces that Bill Chen has given notice to resign from his position as Chief Financial Officer ("CFO") of the Company effective December 31, 2006 for personal reasons.

December 6, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today announced IRB (Institutional Review Board) approval to begin enrolling patients for a Phase II human clinical trial evaluating the Company’s lead product AL-108. The trial will evaluate the efficacy of AL-108 in improving cognitive function in patients who suffer from Mild Cognitive Impairment (MCI), often a pre-cursor to Alzheimer’s disease.

December 6, 2006
VANCOUVER, Dec. 6 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF) (the "Company") has closed its previously announced offering, on a bought deal basis, of units at a price of $0.60 per unit. The 15% underwriter over-allotment option was exercised in full resulting in the issuance of a total of 19,262,500 units for gross proceeds of approximately $11.6 million.

December 6, 2006
Vancouver, December 6, 2006 - BC Advantage Funds (VCC) Ltd. announced today that at a meeting held December 5, 2006 the shareholders of the Advantage Life Science Venture Fund approved the distribution of a special dividend of $10.00 per share on all shares of the fund.

December 5, 2006
Vancouver, BC (December 5, 2006) - Network Immunology Inc. (the “Company” or “Network Immunology”), a privately held biotechnology company developing a vaccine against HIV/AIDS, today announced very positive interim results from its preclinical vaccine trials involving mice.

December 5, 2006
OTTAWA, Dec. 5 /CNW Telbec/ - The Honourable Maxime Bernier, Minister of Industry, today announced the three recipients of the Networks of Centres of Excellence (NCE) awards for innovation in research, knowledge transfer and commercialization. Dr. Christian Messier of Montréal was awarded the NCE Chairs' Award for his groundbreaking work in forestry. Dr. Marlene Bagatto of London and Dr. Brett Poulis of Victoria were awarded the NCE Young Innovator Award, recognizing each of their outstanding achievements in putting their scientific innovations to work for Canadians.

December 5, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced that its annual general meeting to be held on Friday, December 8, 2006 at 10:00 a.m. PST/1:00 p.m. EST at The Four Seasons Hotel, 791 West Georgia Street, Vancouver, B.C., will be available by webcast. Securities analysts, shareholders and the general public are invited to access the live webcast via Inflazyme’s website at www.inflazyme.com or through www.InvestorCalendar.com. The event will be archived and available for replay until December 8, 2007.

December 4, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the topline results from the US Phase II trial of its cholesterol-lowering drug, FM-VP4. Preliminary data received over the weekend confirmed the drug is dose responsive, produces a statistically significant reduction in LDL (or bad) cholesterol and has maintained an excellent safety profile.

December 4, 2006
VANCOUVER, Dec. 4 /CNW/ - Perceptronix Medical Inc. ("Perceptronix") announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services' Victoria Drive Patient Service Centre in Vancouver.

December 1, 2006
Media Release - December 01, 2006 - The University of Victoria-owned Vancouver Island Technology Park (VITP) delivered a major boost to the Island and provincial economy in 2005 by generating more than 2,000 jobs and $280 million in direct, indirect and induced revenue, according to a new economic impact study released today. The report predicts even more growth in the next two years. The impact study, the VITP's first, demonstrates the significance of the high tech industry to the Vancouver Island economy.

December 1, 2006
VANCOUVER, Dec. 1 /CNW/ - QLT USA, Inc., a subsidiary of QLT Inc. (NASDAQ: QLTI; TSX: QLT), announced today that the Eligard(R) 45 mg six-month formulation has been approved in Germany.

November 30, 2006
VANCOUVER, Nov. 30 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP), today announced that it has priced its previously announced offering of US $325 million in aggregate principal amount of senior floating rate notes due 2013. The offering is being made in a private placement.

November 30, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today announced that it has completed the second and final closing of its recently announced private placement. The Company increased the size of this placement to $10.02 million by issuing an additional 1,275,000 units at a price of $0.80 per unit generating additional proceeds of $1.02 million. On November 14th, 2006 the Company announced the completion of a first closing of the private placement issuing 11,250,000 for proceeds of $9.0 million after agreeing to increase the initial $8.0 million offering to meet demand.

November 29, 2006
SANTA CRUZ, CALIFORNIA--(CCNMatthews - Nov. 29, 2006) - Technology Vision Group LLC (TVG) is pleased to announce that as BioPartnering North America (BPN: http://www.techvision.com/bpn) enters its fifth year, its popularity continues to grow as it attracts top international players from the biotechnology, pharmaceutical and financial industries.

November 29, 2006
Vancouver, British Columbia, November 29, 2006 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today reported financial results and operating highlights for the third quarter ended September 30, 2006.

November 29, 2006
Vancouver, British Columbia, November 29, 2006 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today that it has successfully completed its previously announced unit offering with the issue of 18,349,500 units at a price of $0.50 per unit for total gross proceeds of $9,174,750. Each unit comprises one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of Protox at a price of $0.65 on or before 29 November 2008.

November 29, 2006
VANCOUVER, Nov. 29 /CNW/ - Med BioGene Inc. (TSX Venture: MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, today reported that it appointed John H. Rayson, M.D. as its new Chairman of the Board and further reported its financial results for the three months ending September 30, 2006.

November 28, 2006
Vancouver, B.C., Canada – November 27, 2006 - Inimex Pharmaceuticals, Inc. is pleased to announce that Inimex scientific co-founder Dr. R.E. (Bob) Hancock has been awarded the Michael Smith Prize as Canadian Health Researcher of the Year by the Canadian Institute of Health Research (CIHR) for his research on ways of battling infectious diseases in hospitals and nursing homes.

November 28, 2006
November 28, 2006 - Vancouver, British Columbia - A major national research project, co-led by Drs. Bruce Carleton and Michael Hayden, to improve drug safety for children, today received a major contribution of $500,000 from Pfizer Canada Inc. The project, named Genotype-Specific Approaches to Therapy in Childhood (GATC), receives major funding from a Genome Canada/Genome BC-sponsored research program and is led from two research centres within the Child & Family Research Institute (CFRI) at BC Children’s Hospital.

November 28, 2006
VANCOUVER, Nov. 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) announced today that Dr. Bruce Carter has been appointed to its board of directors. Concurrent with the addition of Dr. Carter to the board of directors, Dr. Julia Levy is retiring from the board and becoming Director Emerita. Dr. Levy will continue to be actively involved in QLT's Scientific Advisory Board.

November 27, 2006
Media Release | Nov. 27, 2006 - Researchers at the University of British Columbia and its clinical academic campuses have earned more than $26.5 million to fund facilities and equipment for six projects, from the federal Canada Foundation for Innovation (CFI).

November 27, 2006
VANCOUVER, Nov. 27 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it intends to offer US $325 million in aggregate principal amount of senior floating rate notes due 2013 in a private placement, subject to market and other conditions. The notes will be the company's unsecured senior obligations and will rank equally in right of payment to all of the company's existing and future senior indebtedness.

November 24, 2006
Vancouver, BC – INEX Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that the British Columbia Supreme Court issued a favourable written ruling from the November 7 and 8, 2006 hearing with respect to the spin-out of Tekmira Pharmaceuticals Corporation (“Tekmira”).

November 24, 2006
Ottawa (November 24, 2006) – Canada’s biotechnology industry foresees positive potential in several key policy commitments announced in the federal government’s economic update yesterday.

November 21, 2006
Vancouver, British Columbia, November 21, 2006 – Data supporting Protox Therapeutics Inc.’s (TSX-V: PRX) PORxin technology and its lead compound, PRX302, were presented at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” held in Prague, Czech Republic, November 9th & 10th.

November 21, 2006
VANCOUVER, Nov. 21 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that Mr. Bashir Jaffer has been appointed to serve as the Company's new Chief Financial Officer (CFO).

November 21, 2006
VANCOUVER, BC. November 21, 2006 - Forbes Medi-Tech awarded a contract to 2Paths Solutions to create a distributed supplier inventory tracking and management system that complies with Sarbanes-Oxley regulatory requirements.

November 20, 2006
Victoria, BC, Canada – November 20, 2006 – GenoLogics Life Sciences Software Inc. (GenoLogics), a leading developer of lab and data management software solutions, today announced that the University of Glasgow’s Sir Henry Wellcome Functional Genomics Facility (SHWFGF), recently installed GenoLogics’ Proteus solution for their proteomics research and will be adding the Geneus solution to tackle their genomics research projects in the near future.

November 20, 2006
OTTAWA, ONTARIO--(CCNMatthews - Nov. 20, 2006) - The Board of Directors of BioProducts Canada, a not-for-profit corporation, announced today its recent decision to merge the operations of BioProducts Canada into BIOTECanada, the national biotechnology association.

November 16, 2006
VANCOUVER, BC & SAN DIEGO, CA, Nov. 16 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), has entered into an agreement with Canaccord Capital Corporation for the purchase, on a bought deal basis, of 16,750,000 Units of the Company at a price of $0.60 per Unit, for aggregate gross proceeds of $10,050,000.

November 16, 2006
VANCOUVER, Nov. 16 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has submitted an application for a CE Mark for its Vascular Wrap(TM) paclitaxel-eluting mesh / ePTFE vascular graft combination product on the strength of the results from its European first-in-man study.

November 15, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced it has successfully concluded a first closing of a private placement by issuing 11,250,000 units at a price of $0.80 per unit generating total gross proceeds of $9.0 million. On Wednesday, October 25th, 2006 the Company had announced the launch of an $8.0 million private placement and the company agreed to increase the offering to meet this demand.

November 15, 2006
Victoria, BC, Canada – November 15, 2006 – GenoLogics Life Sciences Software Inc. (GenoLogics), a leading developer of lab and data management software solutions, today announced the ProMeta Interfaculty Centre for Proteomics and Metabolomics at Belgium’s University of Leuven has selected GenoLogics’ Proteus™ as the lab and scientific data management solution for its proteomics and metabolomics research.

November 15, 2006
OTTAWA, Nov. 15 /CNW Telbec/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased to announce the appointment of Philip Blake, President and Chief Executive Officer (CEO) of Bayer Inc., as Chairman of the Board of Directors. Mr. Blake assumed the Board chairmanship during today's Rx&D Annual General meeting held in Toronto.

November 15, 2006
VANCOUVER and SAN DIEGO, Nov. 15 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has issued its 19th CEO Message from Jim DeMesa, MD, President & CEO.

November 14, 2006
VANCOUVER, Nov. 14 /CNW/ - Chemokine Therapeutics Corp. (the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced the financial and operating results of the third quarter ended September 30, 2006.

November 14, 2006
In May 2006, Rick Warner assumed his duties as Manager of NSERC-Pacific in Vancouver. In October, Pam Giberson joined as the Research Development and Promotion Officer and Megan Griffith as the Administrative Officer. NSERC-Pacific will be a resource for the business and academic community in British Columbia and the Yukon.

November 14, 2006
Vancouver, Canada – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the three and nine-month periods ended September 30, 2006. Comparative periods for these statements are the three months and nine months ended September 30, 2005, respectively. All amounts are in Canadian Dollars unless otherwise noted.

November 14, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced its second quarter financial results for the period ended September 30, 2006.

November 13, 2006
Vancouver, Canada, November 13, 2006 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the third quarter ended September 30, 2006. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). At close of business on September 30, 2006, the exchange rate was CAD$1.00 = US$0.8947.

November 10, 2006
Vancouver, Canada, November 10, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report 2006 third quarter financial results on the afternoon of Monday, November 13, 2006. Cardiome will hold a teleconference call and webcast at 4:30pm EST (1:30pm PST) on that day to discuss the results.

November 10, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) will host a conference call to provide a shareholder update and to discuss its financial results for the second quarter ended September 30, 2006 on Wednesday, November 15, 2006 at 8:00 am PST/11:00 am EST.

November 9, 2006
VANCOUVER, Nov. 9 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced today the results from its European first-in-man study for its Vascular Wrap(TM) paclitaxel-eluting product.

November 9, 2006
VANCOUVER, Nov. 9 /CNW/ - ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM: OBP) (the "Company") is pleased to announce that it has closed the short form prospectus offering (the "Offering") of 6,250,000 common shares of the Company (the "Common Shares") at a price of CDN$1.60 per Common Share for aggregate gross proceeds to the Company of CDN$10 million. A syndicate led by Canaccord Capital Corporation and including Desjardins Securities Inc. and Pacific International Securities Inc. (collectively, the "Underwriters") acted as underwriters in connection with the Offering.

November 8, 2006
Media Release: November 8, 2006 - A University of Victoria research team is receiving $4 million over the next five years to develop a new technology for the identification of molecules critical to the early detection of breast cancer.

November 8, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced it had successfully completed patient enrolment in its Phase IIb trial with IPL512,602 for the treatment of moderate to severe asthma. This international study enrolled 218 subjects at centers in the US, Russia, Poland, Bulgaria and the Ukraine. The study began in May 2006 and it is on track to complete in Q1 2007 with top line results expected shortly thereafter.

November 7, 2006

November 7, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Nov. 7, 2006) - Technology Vision Group LLC (TVG) is pleased to announce that it is accepting applications to present at the 5th Annual BioPartnering North America (BPN), which will be held in Vancouver, B.C., Canada, on February 4-6, 2007, and co-hosted again this year by BC Biotech, BioAlberta and BIOTECanada.

November 7, 2006
CAMBRIDGE, MA and VANCOUVER, BC, Nov. 7 /CNW/ - Genzyme Corporation (Nasdaq: GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the completion of Genzyme's tender offer to acquire all of the outstanding shares of AnorMED for $13.50 per share, or approximately $584 million. All of the conditions to Genzyme's tender offer were satisfied, and Genzyme has accepted for payment and paid for approximately 41.5 million shares, or 96 percent of shares outstanding, tendered in the offer.

November 7, 2006
TOKYO, Japan (November 7, 2006) - Pfizer Japan today announced that Pfizer Inc. Chairman Hank McKinnell was decorated with the Grand Cordon of the Order of the Rising Sun by Emperor Akihito. The conferment ceremony was held in the Pine Room, the main ceremony venue, in the Imperial Palace.

November 3, 2006
VANCOUVER, Nov. 3 /CNW/ - ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM:
OBP) (the "Company") is pleased to announce that it has received a receipt for a final short form prospectus filed in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the "Qualifying Provinces") qualifying the distribution (the "Offering") of 6,250,000 common shares of the Company at a price of CDN$1.60 per share for aggregate gross proceeds to the Company of CDN$10 million. A syndicate led by Canaccord Capital Corporation and including Desjardins Securities Inc. and Pacific International Securities Inc. (collectively, the "Underwriters") will act as underwriters in connection with the Offering.

November 2, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced UK’s largest retailer, Tesco Stores Ltd (Tesco), has added to its successful range of cholesterol reducing dairy products by launching a strawberry flavored yogurt drink incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™. The strawberry flavored yogurt drink will be marketed under the Tesco private label brand and is the second Reducol™-based product listing for Tesco in the yogurt drink category.

November 1, 2006
VANCOUVER, Nov. 1 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced financial results for the third quarter ended September 30, 2006.

November 1, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that dosing has been completed in a Phase Ib human clinical trial evaluating the Company’s product AL-108 as a treatment for Alzheimer’s disease.

October 31, 2006
Vancouver, Canada, October 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Cardiome management will present an overview of Cardiome at two upcoming investor conferences.

October 27, 2006
VANCOUVER, Oct. 27 /CNW/ - iCo Therapeutics Inc. announced today that Dr. David S. Boyer will join its strategic advisory team. As an ophthalmologist and senior partner of the Retina-Vitreous Associates Medical Group in California, Dr. Boyer specializes in diseases of the retina and vitreous. He is a Clinical Associate Professor of Ophthalmology at the University of Southern California and has worked on trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.

October 27, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it has closed its acquisition of TheraPei Pharmaceuticals, Inc. originally announced October 25, 2006, and that Dr. John Nestor has now taken up his new position as Forbes’ Chief Scientific Officer. Forbes issued a total of 94,672 common shares and paid cash of approximately US $400,000 on closing. Forbes also changed the name of TheraPei to “Forbes Medi-Tech (Research) Inc.”.

October 26, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that Charles Butt, President and CEO, will be presenting at the upcoming Rodman & Renshaw Techvest 8th Annual Healthcare Conference in New York on November 6, 2006.

October 26, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the third quarter ended September 30, 2006 and reiterated its strategic plan to focus the Company on its ocular business and to reduce expenses. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

October 26, 2006
VANCOUVER, Oct. 26 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, reports that research presented this week at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the world's largest interventional vascular medicine meeting, further supports the safety and efficacy of Drug Eluting Stents and in particular TAXUS(R) paclitaxel-eluting coronary stent systems.

October 26, 2006
VICTORIA, Oct. 26 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV - News; TSX: ASV - News), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases today announced that based on a preliminary review of the data, CellCept® (mycophenolate mofetil or MMF) in treating myasthenia gravis (MG) failed to meet both primary and secondary endpoints in its phase III trial.

October 25, 2006
VANCOUVER, Oct. 25 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) today filed a Form 6-K (the "Form 6-K") with the U.S. Securities and Exchange Commission ("SEC"), which contains its financial statements for the years ended December 31, 2005 and 2004 and the fifteen months ended December 31, 2003 and as of December 31, 2005 and 2004, and its financial statements for the six months ended June 30, 2006 and 2005 (together, the "Angiotech Statements").

October 25, 2006
VANCOUVER, Oct. 25 - Protox Therapeutics Inc. (TSX-V:PRX) ("Protox") announced today that it intends to raise $8 million to $10 million (CDN) through a private placement of Units at $0.50 per Unit. The private placement will be sold through Jennings Capital Inc. and Canaccord Capital Corporation as agents.

October 25, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has engaged a syndicate of agents co-led by Blackmont Capital and Clarus Securities and including Sprott Securities to raise approximately $8-million through a private placement of units priced at $0.80 per unit.

October 25, 2006
The University of Victoria has attracted one of the world’s leading protein chemists to head the UVic-Genome British Columbia Proteomics Centre.

October 25, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (Forbes) (TSX:FMI and NASDAQ:FMTI) today announced that it has signed an agreement to acquire 100% of TheraPei Pharmaceuticals, Inc.(TheraPei) of San Diego, California. TheraPei is a privately held company formed with technology ‘spun-out’ of Sequenom, Inc. (NASDAQ: SQNM) focused on developing novel pharmaceuticals directed at the underlying causes of type II diabetes and related metabolic diseases. Forbes will further develop TheraPei technologies along with Forbes’ existing technologies with R&D based in San Diego and Forbes’ clinical development team in Vancouver. TheraPei’s founder, Dr. John Nestor, will be appointed as the Chief Scientific Officer of Forbes on closing.

October 24, 2006
VANCOUVER, Oct. 24 /CNW/ - Ondine Biopharma Corporation (TSX: OBP, AIM: OBP) (the "Company") is pleased to announce that it has filed a preliminary short form prospectus in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the "Qualifying Provinces") qualifying the distribution (the "Offering") of 6,250,000 common shares of the Company at a price of CDN$1.60 per share for aggregate gross proceeds to the Company of CDN$10 million. A syndicate led by Canaccord Capital Corporation and including Desjardins Securities Inc. and Pacific International Securities Inc. (collectively, the "Underwriters") will act as underwriters in connection with the Offering.

October 23, 2006
Vancouver, British Columbia – Zymeworks Inc., a privately held biotechnology Company developoing cutting-edge proprietary computational technology for ‘designer’ enzyme research and development, is proud to announce the addition of Dr. Patrick McCroskey to it Board of Directors.

October 23, 2006
BURNABY, BC, Oct. 23 /CNW/ - Welichem Biotech Inc. ("WBI" or the "Company") (TSX-V: WBI) announces that it has engaged Mr. Larry Morningstar to provide investor relations services for the Company. Mr. Morningstar will initiate and maintain contacts with the financial community, shareholders, investors and other stakeholders as part of his role to increase public awareness of the Company.

October 23, 2006
Vancouver, British Columbia — AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second pivotal Phase III clinical trial evaluating its proprietary product MOZOBIL in cancer patients, and that the Company is on track to meet its schedule of releasing top-line data from both Phase III trials in the first half of 2007. If the Phase III trials are successful, it would be possible to file for marketing approval with the United States Food and Drug Administration (FDA) in the second half of 2007 and with regulators in Canada and Europe in 2008.

October 20, 2006
VANCOUVER, Oct. 20 /CNW/ - ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM:
OBP) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Canaccord Capital Corporation and including Desjardins Securities Inc. and Pacific International Securities Inc., which have agreed to purchase, on a bought deal basis, 6,250,000 common shares of the Company at a price of C$1.60 per share, for aggregate gross proceeds of C$10 million.

October 19, 2006
VANCOUVER, CANADA-QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT’s Visudyne® (verteporfin) product of US$75.1 million for the quarter ended September 30, 2006. This represents a decrease of 39.3% over sales in the third quarter of 2005 and a 21.2% decline compared to the second quarter of 2006. Visudyne sales in the U.S. for the quarter were approximately US$11.0 million, representing 14.6% of total sales for the quarter.

October 18, 2006
A University of British Columbia industry collaboration that produced a therapeutic device implanted in more than two million coronary heart disease patients has earned a Synergy Award for Innovation from the Natural Sciences and Engineering Research Council (NSERC).

October 17, 2006
Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the Company’s cholesterol-lowering drug, FM-VP4, has been recognized as one of “Windhover’s Top 10 Unpartnered Cardiovascular Projects” for 2006.

October 17, 2006
VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /CNW/ - Genzyme Corporation (Nasdaq: GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today that they have executed a mutually beneficial support agreement under which Genzyme will acquire AnorMED in an all cash transaction valued at US$13.50 per outstanding share, or approximately US$580 million.

October 17, 2006
enGene, Inc., a privately held biotechnology company with a highly innovative approach for the treatment of diabetes called GEMS™-Insulin, announced today it has acquired a license to a non-viral gene integration technology from Poetic Genetics, Inc. of Burlingame, California.

October 17, 2006
Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce completion, on October 15, 2006, of the 28-day, repeat dermal application study on mini-pigs for the Company's lead drug candidate ("WBI-1001") targeting psoriasis.

October 17, 2006
Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce the completion of its Annual and Special General Meeting of Shareholders ("AGM"), held yesterday in Vancouver, B.C.

October 17, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today an updated timeline for the closing of the spin-out of Tekmira Pharmaceuticals Corporation (“Tekmira”). On September 20, 2006 shareholders of INEX voted 99.3% in favour of spinning out all of the Company’s technology, products, cash and partnerships into Tekmira.

October 16, 2006
Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that a new preclinical study demonstrates the potential of the Company’s proprietary compounds to partially repair brain damage that results from a key marker of pathology seen in Alzheimer's disease and other types of neurodegeneration.

October 11, 2006
VANCOUVER, Oct. 11- Protox(TM) Therapeutics Inc. (TSX-V:PRX) announced today that it has received approval of their Clinical Trial Application (CTA) from Health Canada to initiate a Phase I human clinical trial of PRX302 to treat adult men with benign prostatic hyperplasia (BPH), or enlarged prostates.

October 11, 2006
VANCOUVER, Oct. 11 /CNW/ - AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it today received an irrevocable offer from Genzyme Corporation (NASDAQ:GENZ) and its wholly owned subsidiary, Dematal Corp., to enter into the agreed upon form of support agreement whereby Dematal will, subject to certain conditions, amend its tender offer to acquire all of the outstanding shares of AnorMED by, among other things.

October 10, 2006
Vancouver, Canada, October 10, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission on Form F-10.

October 10, 2006
VANCOUVER, Oct. 10 /CNW/ - AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) announced today that it has received a proposal from Genzyme Corporation (NASDAQ:GENZ), acting through its wholly owned subsidiary, Dematal Corp. ("Genzyme"), to acquire all of the outstanding shares of AnorMED by amending the bid price of its existing tender offer from US$8.55 to US$13.50 per share. Genzyme's proposal indicates that the transaction would be fully financed from its existing cash and that the transaction is not subject to any financing contingency or financing arrangements.

October 6, 2006
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that the United States Court of Appeals for the Federal Circuit issued a decision reversing the district court’s partial summary judgment ruling on one issue of inventorship on the patent that is in dispute in the lawsuit commenced in 2001 by Massachusetts Eye and Ear Infirmary (“MEEI”) in the United States District Court of the District of Massachusetts.

October 6, 2006
Vancouver, BC - (October 5, 2006) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announces that in connection with its previously announced Rights Offering, expected to be made towards the end of October, 2006, its Board of Directors decided on September 29, 2006 to amend the terms of its 1,877,999 stock options previously granted to employees and consultants (other than insiders).

October 5, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that Champion, based in France (a Groupe Carrefour banner), will be creating five new dairy products containing Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol(tm). The following products will be launched on the market through Champion stores: original and strawberry flavored yogurt drinks, a mixed strawberry and apricot flavored yogurt, and an all natural (fruit base) set yogurt. The Carrefour superstores will sell these products under their brand name Agir Nutrition.

October 5, 2006
VANCOUVER, Oct. 5 /CNW/ - AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) announced today that its Board of Directors has recommended that AnorMED shareholders accept and tender their shares to the offer by Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM), filed today with applicable securities regulators and being mailed to shareholders, to purchase all of the outstanding common shares of AnorMED including all common shares issuable on the exercise of outstanding stock options, for US$12.00 per share in cash. The Millennium offer expires on November 10, 2006.

October 4, 2006
VANCOUVER, Oct. 4 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced results from a prospective, randomized, controlled, blinded clinical trial of its Periowave(TM) Photodynamic Disinfection (PDD) System for the treatment of periodontal diseases. Results showed significant improvement in pocket depth, clinical attachment level and bleeding on probing when compared to the gold standard of scaling and root planing (SRP).

October 4, 2006
VANCOUVER, Oct. 4 /CNW/ - AnorMED Inc. (NASDAQ:ANOR; TSX: AOM) said today it has received a proposal from Genzyme Corporation (NASDAQ:GENZ) to increase its tender offer price from US$8.55 per share in cash to a price in excess of US$12.00 per share in cash to purchase through a wholly-owned subsidiary all of the issued and outstanding common shares of AnorMED.

October 3, 2006
Vancouver, BC – September 19, 2006 – Flintbox, the premiere online application for marketing and licensing academic research and innovation in Canada, today announces that BC Biotech has chosen Flintbox as the platform to develop a searchable online directory of biotechnologies developed in British Columbia.

October 3, 2006
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- October 03, 2006 -- enGene, Inc., a privately held biotechnology company developing an innovative approach for the treatment of diabetes called GEMS™-Insulin, announced today that Dr. Christopher J. Rhodes and Dr. Imre Kovesdi have joined the company as Scientific Advisors. The addition of Drs. Rhodes and Kovesdi further bolsters the Company's expertise in the areas of diabetes and gene therapy.

October 2, 2006
Vancouver, Canada (October 2) and Osaka, Japan (October 3) --- Xenon Pharmaceuticals Inc. (Xenon) and Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies have entered into an exclusive agreement to develop and commercialize oral formulations of Xenon’s lead product for pain, XEN401, in Japan and certain Asian countries. XEN401 is currently in preclinical development.

October 2, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the completion of its US Phase II trial for its cholesterol-lowering drug, FM-VP4. The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12. The results are anticipated to be released in mid-to-late fourth quarter 2006.

October 1, 2006
VANCOUVER, BC, Oct. 2 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that it has received CE Mark approval for expanded use of its Photodynamic Disinfection system. The new indication is for decolonization of pathogenic bacteria such as methicillin-resistant Staphyloccocus aureus (MRSA) in the nose. This novel approach has the potential to decrease the rate of nosocomial infection, while avoiding development of antibiotic resistance.

September 29, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) will host its Annual General and Special Shareholders’ Meeting on Friday, December 8, 2006.  Additional details will be provided closer to the meeting date.

September 29, 2006
Calgary, AB (September 29th, 2006) — A combination stent-drug delivery vehicle developed by two Vancouver MDs is saving the lives of cardiovascular disease patients worldwide.

September 28, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it is working to close the spin-out of Tekmira Pharmaceuticals Corporation (“Tekmira”) by the end of October 2006. On September 20, 2006 shareholders of INEX voted 99.3% in favour of spinning out all of the Company’s technology, products, cash and partnerships into Tekmira.

September 27, 2006
VANCOUVER, CANADA (SEPTEMBER 27, 2006) – The Board of Directors of Perceptronix Medical Inc. (“Perceptronix”) is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO, effective September 25, 2006.

September 27, 2006
Vancouver, Canada, September 27, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that RSD1235 has been assigned the name vernakalant hydrochloride by the United States Adopted Names (USAN) Council. All future references to RSD1235 (iv) will now be vernakalant (iv), and references to RSD1235 (oral) will be vernakalant (oral). The commercial brand name for vernakalant (iv) will be finalized in the coming months.

September 27, 2006
VANCOUVER, BC and SAN DIEGO, CA, Sept. 27 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases will have five posters related to the company's lipopeptide compound, MX-2401 presented at the American Society for Microbiology's 46th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being held in San Francisco September 27th-30th, 2006.

September 27, 2006
VANCOUVER, September 27th, 2006 - Allon Therapeutics Inc. (TSX: "NPC"), the "Neuro Protection Company", announced today that it has been granted an Australian patent for its class of compounds that has shown promise in the improvement of learning and memory.

September 26, 2006
Vancouver, British Columbia — AnorMED Inc. ( NASDAQ:ANOR; TSX: AOM) today announced its Board of Directors has entered into a support agreement with respect to a planned tender offer by a wholly-owned subsidiary of Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) under which Millennium would acquire all of the outstanding common shares of AnorMED, including all common shares issuable on the exercise of outstanding stock options, for US$12.00 per share in cash.

September 26, 2006
VANCOUVER, BC, CANADA & SAN DIEGO, CA, USA, Sept. 26 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will make a presentation at the UBS 2006 Global Life Sciences Conference being held in New York City September 25-28, 2006. Dr. Jim DeMesa, President and Chief Executive Officer, will present a corporate overview on September 28th at 11:30am (ET) in Ballroom A of the Grand Hyatt New York.

September 25, 2006
Med BioGene enters development and validation phase for its Cardiovascular Disease Profiling System(TM); begins joint pilot project with Ottawa Heart Institute Research Corporation

September 21, 2006
Vancouver, Canada, September 21, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Bob Rieder, Chief Executive Officer, will present an overview of Cardiome at the UBS Global Life Sciences Conference in New York at 1:30pm EST (10:30am PST) on Tuesday, September 26, 2006.

September 21, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced that at its Special Meeting of Shareholders held yesterday, shareholders of INEX approved the Plan of Arrangement to spin-out all of the Company’s technology, products, cash and partnerships into a new company, Tekmira Pharmaceuticals Corporation ("Tekmira"). Shareholders voted 99.3% in favour of the spin-out. Shareholders also approved an amendment to the INEX stock option plan, which will be adopted as the Tekmira stock option plan on the completion of the spin-out.

September 21, 2006
VANCOUVER, Sept. 21 - Protox(TM) Therapeutics Inc. (TSX-V:PRX) announced today that it has submitted a Clinical Trial Application (CTA) to Health Canada for PRX302, lead candidate in the Company's PORxin(TM) technology platform. Upon clearance from Health Canada, Protox intends to commence a Phase I clinical trial of PRX302 for the treatment of benign prostatic hyperplasia (BPH), a condition commonly known as enlarged prostate.

September 21, 2006
Media Release | Sep. 21, 2006 - In the last month, the University of British Columbia has scored eighth, 27th and 36th in surveys that compare the world’s best research universities.

September 20, 2006
VANCOUVER, Sept. 20 /CNW/ - AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) announced yesterday at its Annual General Meeting of Shareholders that the Company remains on track to meet its clinical and commercialization milestones, and commented on the process of realizing maximum value for shareholders through strategic alternatives.

September 20, 2006
Vancouver, September 20, 2006 - Eight British Columbia-based companies were honoured as Canada’s fastest growing technology companies on the 2006 Deloitte Technology Fast 50 - the annual program that recognizes Canadian technology companies for their innovation and growth.. British Columbia fielded the second highest number of winners to the Fast 50 program along with Quebec.

September 20, 2006
Vancouver, BC - (September 20, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") announced today that it had commenced legal proceedings against Tianjin Fairwood Mfg. Co. Ltd. ("Tianjin") arising out of a transaction concluded in November, 2001 whereby the Company issued to Tianjin 2,598,425 WEX shares in exchange for the transfer by Tianjin of a 46% interest in the Company's subsidiary Nanning Maple Leaf Pharmaceuticals Inc. ("NMLP"). The claim against Tianjin seeks the return of the WEX shares.

September 19, 2006
VANCOUVER, Sept. 19 /CNW/ - AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced it will receive U.S. $10 million in cash in consideration for amending the license agreement for its proprietary anti-cancer drug picoplatin (NX473) to expand the licensed territories to worldwide, forego future development milestones and reduce royalty payments.

September 19, 2006
VANCOUVER, Sept. 19 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that Erinn B. Broshko, Chief Executive Officer, will be presenting at BioContact Québec 2006 (www.biocontact.qc.ca) in Québec City. BioContact is a biopharmaceutical partnership symposium with over 1200 participants.

September 18, 2006
Vancouver, British Columbia — AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that under the terms of an existing agreement, AnorMED will receive a U.S.$3 million milestone payment from Shire Pharmaceuticals Group, plc based on the recent licensing approval received in Germany by Shire to sell FOSRENOL as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.

September 18, 2006
VANCOUVER, SEPTEMBER 18,2006 – Dr. Bruce McManus has been appointed Director of the James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research and Scientific Director of the Heart Centre at Providence Health Care, effective September 1, 2006.

September 17, 2006
VANCOUVER, Sept. 17 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced positive preclinical data related to its Vascular Wrap(TM) paclitaxel-eluting mesh and Lifespan(R) graft technology platform at The Western Vascular Society 2006 Annual Meeting in La Jolla, California."We are excited by the potential of the Vascular Wrap paclitaxel-eluting mesh product in a variety of indications, including AV access for hemodialysis patients," said Dr. William Hunter, President and CEO of Angiotech Pharmaceuticals.

September 15, 2006
VANCOUVER, Sept. 15 /CNW/ - AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) today announced that, in accordance with its established policy, the Toronto Stock Exchange ("TSX") has deferred its review of AnorMED's shareholder rights plan. The TSX policy states that, in the context of an active take-over bid, TSX will normally defer its own review until the appropriate securities commission has determined whether or not it will intervene pursuant to National Policy 62-202 of the Canadian Securities Administrators. 

September 15, 2006
MEDIA RELEASE | SEPTEMBER 15, 2006 - An international team of scientists, including seven from the University of British Columbia, has completed the world's first physical map and sequencing of a tree genome - and the third plant ever sequenced - providing important insight into the future development of alternative fuels, forest health and wood quality.

September 14, 2006
VANCOUVER, BC, and SAN DIEGO, CA, Sept. 14 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Friday, September 15th, 2006 at 10:30 a.m. ET (7:30 a.m. PT) to discuss financial results for the first fiscal quarter ended July 31, 2006. An update on company activities will also be provided.

September 14, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced the final results of its modified "Dutch Auction" tender offer, which expired at 5:00 p.m., Eastern Time, on Friday, September 8, 2006.

September 13, 2006

Vancouver, Canada, September 13, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced top-line results from both the 300mg and 600mg dosing groups for its recently-completed Phase 2a pilot study of RSD1235 (oral). The study was initiated in December 2005, and an interim analysis of the 300mg dosing group relative to the initial placebo group was announced on July 24, 2006. 


September 13, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced the appointment of Jeremy Curnock Cook as the Chairman of the Board of Directors effective immediately. Mr. Curnock Cook succeeds John Hodgman who served as Inflazyme’s Chairman since November 2005. Mr. Hodgman has resigned his position due to increased commitments resulting from his recent appointment as Senior Vice President and Chief Financial Officer at InterMune Inc., in California. The Board of Inflazyme wishes to thank John for his stewardship of the Company for the last several months.

September 13, 2006
VICTORIA, Sept. 13 /PRNewswire-FirstCall/ -- Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall, President and Co-Founder, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, England.

September 12, 2006
Vancouver, Canada – September 12th, 2006 - Xenon Pharmaceuticals Inc., a privately held company engaged in developing novel small molecule therapies for select neurological, cardiovascular and metabolic diseases, today announced that Takeda Research Investment, Inc.

September 12, 2006

Vancouver, Canada, September 12, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a teleconference call and webcast will be held on Wednesday, September 13, 2006 at 8:00am EST (5:00am PST) to discuss results from the Phase 2a pilot study for RSD1235 (oral). A press release will be issued prior to the call.


September 12, 2006
VICTORIA, Sept. 13 /CNW/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall, President and Co-Founder, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, England.

September 12, 2006
BURNABY, BC, Canada, September 12, 2006 - Twinstrand Therapeutics announced today that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning.

September 11, 2006
There have been a number of positive developments affecting the Company since
my last letter to shareholders and I wanted to share with you some of these developments
and re-iterate my vision for the future.

September 11, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has become aware of a statement of claim filed by Protiva Biotherapeutics Inc. (“Protiva”) in California Superior Court. Protiva, a private biotechnology company, was spun-out from INEX in 2001 along with certain intellectual property rights relating to gene therapy technology. INEX holds a minority interest in Protiva.

September 11, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced the preliminary results of its modified "Dutch Auction" tender offer, which expired at 5:00 p.m., Eastern Time, on Friday, September 8, 2006.

September 8, 2006
Vancouver, BC - (September 7, 2006) - WEX Pharmaceuticals Inc. (“WEX” or the
“Company”) confirms that the meeting materials for the upcoming Shareholders'
Meeting (“Meeting”) to be held on Friday, September 29, 2006 have been mailed
to its shareholders.

September 7, 2006
Vancouver, Canada, September 7, 2006 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Bear Stearns 19th Annual Healthcare Conference in New York at 10:00am EST (7:00am PST) on Tuesday, September 12, 2006.

September 7, 2006
SAN DIEGO, CA, Sept. 7 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the presentation of positive results from a clinical trial examining the safety and efficacy of HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on HIV-negative men with internal anal condyloma or genital warts.

September 7, 2006
VANCOUVER, Sept. 7 /CNW/ - AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that its common shares will begin trading on September 8, 2006 on the NASDAQ Global Market of the NASDAQ Stock Market, Inc. under the symbol "ANOR". Concurrent with trading on NASDAQ, AnorMED's common shares have been de-listed from the American Stock Exchange.

September 6, 2006
SAN DIEGO, CA, Sept. 6 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the presentation of preclinical data on HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases. The data demonstrated greater potency and specific activation of the immune response when HspE7 was combined with either of the two adjuvants studied.

September 6, 2006
Burnaby, British Columbia, Canada – Chromos Molecular Systems Inc. (TSX: CHR) has formed a Multiple Sclerosis (MS) Advisory Board to guide the Company’s development of a promising novel treatment for MS. Comprised of nationally and internationally recognized physicians, clinicians and scientists in the MS field, the MS Advisory Board will serve as an independent panel of experts regarding the development of CHR-1103 for the acute treatment of relapses (flares) associated with MS and other follow-on indications related to MS.


September 6, 2006
Vancouver, BC (September 6, 2006) - WEX Pharmaceuticals Inc. ("Wex" or the "Company") is pleased to announce that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada has approved the Company's request to resume the clinical trials for Tectin™. 

September 6, 2006

VANCOUVER - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that Health Canada has completed review of the Company’s Clinical Trial Application for the AL-208 Phase II study. Health Canada will allow the Company to begin recruiting Canadian patients into an ongoing Phase II human clinical trial evaluating its product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery.


September 6, 2006
Press Release - A new IBM (NYSE: IBM) system will assist in the day-to-day delivery of public health services and will help manage the risk of communicable disease in Canada.

September 5, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that Finland based Kesko has expanded their Pirkka range of products containing Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™.

September 5, 2006
VANCOUVER, Sept. 5 /CNW/ - AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) announced that its Board of Directors, based on the recommendation of its Strategic Initiatives Committee, unanimously recommends that AnorMED shareholders reject and not tender their shares to the unsolicited offer by Genzyme Corporation (Nasdaq:GENZ) to acquire all of the outstanding shares of AnorMED for US$8.55 per share in cash.

September 1, 2006
BURNABY, BC, Sept. 1 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce that the Company's board of directors approved on August 31, 2006 a grant of incentive stock options to directors, officers, employees and consultants of the Company for the purchase of up to an aggregate of 2,090,000 common shares of the Company at a price of $0.10 each until August 31, 2011.

August 30, 2006
VANCOUVER, Aug. 30 /CNW/ - AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today announced that its Board of Directors has unanimously rejected an unsolicited approach from Genzyme Corporation ("Genzyme"), to purchase all of the issued and outstanding common shares of AnorMED for U.S. $8.55 per share in cash.

August 30, 2006
Vancouver, B.C. — Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that its partner Hana Biosciences (NASDAQ: HNAB) has enrolled the first patient in a Phase 1 human clinical trial evaluating the safety, tolerability and preliminary efficacy of INX-0125 (sphingosomal vinorelbine) as a treatment for advanced solid tumors.

August 30, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 30, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that Professor Trevor Robbins has been appointed to its Scientific Advisory Board effective August 24th, 2006.

August 30, 2006
VANCOUVER, Aug. 30 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) today reported its financial results for the second quarter ending June 30, 2006.

August 30, 2006
Vancouver, BC, Canada, August 30, 2006 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that it has filed a preliminary prospectus with the securities regulatory authorities in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario with a proposed initial public offering of its common shares. The offering will be made through Canaccord Capital Corporation and Jennings Capital Inc. on a commercially reasonable efforts basis.

August 29, 2006

August 29, 2006
VANCOUVER, British Columbia, August 29, 2006 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent 7,091,310 B2 relating to chemokine analogs for the treatment of human disease.

August 28, 2006
VANCOUVER, Aug. 28 /CNW/ - Ondine Biopharma Corporation ("the Company", TSX: OBP; AIM: OBP) announced today that it has appointed Mr. Thomas G. Leonardi as Vice-President, Sales and Marketing of Ondine Biopharma (USA) Inc.

August 28, 2006
VANCOUVER, Aug. 28 /CNW/ - AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has called the Company's 2006 Annual and Special Meeting of Shareholders to be held on Tuesday, September 19, 2006, at 2:30pm (Pacific Time) in Vancouver, British Columbia, in the Plaza Ballroom of the Hyatt Regency Hotel.

August 28, 2006
VANCOUVER, Aug. 28 /CNW/ - AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has received approval from the NASDAQ Stock Market, Inc. to list its common shares on the NASDAQ Global Market (formerly the NASDAQ National Market) under the symbol "ANOR".

August 25, 2006
Vancouver, BC - (August 24, 2006) - WEX Pharmaceuticals Inc. (the "Company") is pleased to announce that a pre-CTA (Clinical Trial Applications) meeting has been scheduled with the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada on the 5th of September in Ottawa. The purpose of this meeting is to present the results of the new data analysis of the double-blind study (WEX-014) and the long term safety and efficacy study of Tectin(TM) (WEX-014OL) in cancer-related pain. The Company will also discuss the future development of Tectin(TM) with the BGTD.

August 24, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has filed with securities regulators in Canada and mailed to shareholders the information circular and proxy materials for the shareholders’ meeting September 20, 2006 at which INEX will seek approval to spin-out the Company’s technology, products, cash and partnerships into Tekmira Pharmaceuticals Corporation (“Tekmira”).

August 24, 2006
VANCOUVER, Aug. 24 - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that Anthony Boone will join the company as Director of Investor Relations and Corporate Communications. Mr. Boone brings over fifteen years of senior corporate communications experience to the position including ten years with IMS Health Canada, a subsidiary of IMS Health the world's largest provider of information and analysis to the pharmaceutical industry.

August 24, 2006
VANCOUVER, Aug. 24 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP) today announced that it has received CE Mark approval to expand the use for its Contour Threads(TM) product line, encompassing aesthetic as well as plastic and reconstructive surgical procedures. Having already been approved for use in brow, neck and mid-face lift procedures, Angiotech is currently marketing the product for facial procedures through distribution agreements in the EU. Angiotech now has the ability to also market its product line in Europe for breast lift and nipple repositioning procedures.

August 23, 2006
EDMONTON, Aug. 22 /CNW/ - QSV Biologics (QSV), Ltd. Edmonton, Canada, announced today that they have signed a 2nd contract with Tissue Therapies Limited (ASX: TIS) of Brisbane, Australia. This contract is for the cGMP manufacture of clinical quantities of synthetic Vitronectin (one of the components of the VitroGro(R) platform for accelerated wound healing) and a single protein, chimeric form of VitroGro(R), called VitroGro(R)-1.

August 23, 2006
SAN DIEGO, CA, Aug. 23 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that it has signed a supply agreement with Oncovir, Inc ("Oncovir") for a proprietary Oncovir compound known as Hiltonol or Poly-ICLC, an adjuvant that activates innate immunity and targets the Toll-like receptor 3 (TLR-3) pathway.

August 22, 2006
Vancouver, BC - (August 21, 2006) - WEX Pharmaceuticals Inc. (the "Company") is pleased to announce that it has agreed to offer by way of private placement (the "Private Placement") an aggregate of 7,773,584 common shares at a price of $0.265 per share to purchasers in China. Closing is expected to occur on or about September 8, 2006.

August 21, 2006
VANCOUVER, Aug. 21 /CNW/ - Perceptronix Medical Inc. ("Perceptronix") announced today that it has been issued a Class III in vitro Diagnostic Device License from Health Canada for its ClearSign(TM) Sputum Test for the detection of early lung cancer. Perceptronix can now market this test service in Canada as well as in the European Union, having received CE Mark registration in May, 2006.

August 17, 2006
VANCOUVER, Aug. 17 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced today that it will begin enrolment in a clinical trial in the United Kingdom to assess the effectiveness and safety of the Vascular Wrap(TM) paclitaxel-eluting mesh and Lifespan(R) graft technology platform in hemodialysis patients.

August 17, 2006
VANCOUVER, Aug. 17 /CNW/ - iCo Therapeutics Inc. announced today the appointment of Dr. Peter Hnik as Chief Medical Officer. Dr. Hnik is an ophthalmologist with a focus in glaucoma, neuro-ophthalmology, and deep industrial experience in retinal diseases such as age related macular degeneration and diabetic retinopathy.

August 15, 2006
Vancouver, Canada - Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the three and six-month periods ended June 30, 2006. Comparative periods for these statements are the three months and six month periods ended June 30, 2005, respectively. All amounts are in Canadian Dollars unless otherwise noted.

August 14, 2006
Vancouver, Canada, August 11, 2006 - Zymeworks is proud to announce the addition of Dr. Steve Withers to it Scientific Advisory Board. A joint professor of Chemistry and Biochemistry at the University of British Columbia (UBC), Dr. Withers combines biochemistry, organic chemistry and biophysical chemistry to probe and manipulate the structure and mechanism of enzymes.

August 14, 2006
Vancouver, Canada, August 14, 2006 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the second quarter ended June 30, 2006. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). At close of business on June 30, 2006, the exchange rate was CAD$1.00 = U.S. $0.8959.

August 14, 2006
VANCOUVER, Aug. 14 /CNW/ - Ondine Biopharma Corporation ("the Company", TSX: OBP; AIM: OBP) announced today its financial results for the second quarter ended June 30, 2006.

August 14, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 14, 2006) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced its first quarter financial results for the period ended June 30, 2006.

August 14, 2006
VANCOUVER, CANADA (August, 14 2006) – Perceptronix Medical Inc. (“Perceptronix”)
announced today that the National Research Council Canada Industrial Research Assistance
Program (NRC-IRAP) has agreed to provide a financial contribution in support of the
development of its ClearVu™ Elite advanced fluorescence bronchoscopy system.

August 11, 2006
Vancouver, BC - (August 11, 2006) - Earlier this week, two shareholders of the Company who hold in the aggregate less than one-half of one percent of the outstanding shares (the "Dissidents") launched proceedings against the Company following the Company's decision to provide its shareholders with a fair opportunity to evaluate responses to matters raised by the Dissidents in response to the Company's decision to reschedule its Annual General Meeting to September 29, 2006.

August 11, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 11, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today in its second quarter 2006 operating results that it continued to achieve all of its milestones during the second quarter, including the beginning of patient dosing in the Company's first Phase II clinical trial designed to show human efficacy.

August 10, 2006

August 10, 2006
Vancouver, BC (August 10, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") is pleased to announce that the Company has signed the term sheet of the license agreement with Children's Hospital Boston, for the development and commercialization of pharmaceutical(s) containing Tetrodotoxin (TTX) for prolonged local anesthesia based on the patented technology by Children's Hospital.

August 10, 2006
VANCOUVER, Aug. 10 - Protox(TM) Therapeutics Inc. (TSX-V:PRX)announced today that the first two cohorts of patients in its Phase I clinicaltrial for prostate cancer using PRX302 have been treated safely and that doseescalation to the third cohort will commence this month.

August 10, 2006
EDMONTON, Aug. 10 /CNW/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Proteon Therapeutics, Inc, of Waltham, Massachusetts and Kansas City, Missouri, announced today the signing of a contract for the cGMP manufacturing of PRT-201, Proteon's lead drug candidate.

August 9, 2006
SAN DIEGO, CA, Aug. 9 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter ended June 30, 2006. All amounts, unless specified otherwise, are in Canadian dollars.

August 8, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the Company is on track to achieve its 2006 core objectives in both pharmaceutical development and its revenue generating ingredient business.

August 4, 2006
SAN DIEGO, CA, Aug. 4 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that it will receive Cad$2.8 million from GVIC Publications. These funds were being held in escrow in connection with Nventa's corporate reorganization previously announced on March 16, 2006.

August 3, 2006

CANTEST Ltd. announced today the acquisition of Vizon SciTec Inc., a Vancouver-based contract science company with a focus on chemical and biological technology development.


August 3, 2006
VANCOUVER, CANADA - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that it will mail an offer to purchase and issuer bid circular (the "Circular") to its shareholders today in connection with a modified "Dutch Auction" tender offer for up to 13 million common shares, previously announced on July 27, 2006 with the Company's results for the quarter ended June 30, 2006. The Circular is being filed with the securities regulatory authorities in the United States and Canada. The offer to purchase shares will expire on September 8, 2006, at 5:00 p.m. (Eastern Time), unless extended.

August 3, 2006
VANCOUVER, BC — Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) reported today in its second quarter 2006 operating results that the successful negotiation of two partnerships and the settlement of its convertible debt have placed the Company on track to complete its transformation into Tekmira Pharmaceuticals Corporation by the end of September 2006.

August 3, 2006
VANCOUVER, Aug. 3 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced financial results for the second quarter ended June 30, 2006. The second quarter represents the first reporting period that includes the results of operations from the business of American Medical Instruments Holdings, Inc. (AMI), which was acquired by Angiotech in March 2006.

August 3, 2006
VANCOUVER, Aug. 3 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce the results of its pre-clinical studies involving its Diagnostic Lymphoma Bioarray. The studies of fifty RNA samples derived from human lymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray successfully differentiated between genes in both the diseased and healthy control samples.

August 2, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 2, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has filed a Clinical Trial Application (CTA) with Health Canada to gain approval to begin recruiting Canadian patients into its ongoing Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment that commonly occurs following coronary artery bypass graft (MCI post-CABG) surgery.

August 1, 2006
VANCOUVER, Aug. 1 - Protox(TM) Therapeutics Inc. (TSX-V:PRX)announced today that Lions Liquidity Investment Fund has become a newinstitutional investor. The fund, which is managed by Protox Chairman FrankHoller, is purchasing 1,000,000 common shares of the company by way of aprivate transaction with Dr. Tom Buckley, Chief Scientific Officer and founderof Protox. Dr. Buckley, who will be retiring from the company next year, isdivesting the shares for the purposes of estate planning. Post transaction hewill hold 2,780,000 shares and will remain fully committed to his role as headof research until his planned retirement.

August 1, 2006
VANCOUVER, Aug. 1 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that it has received renewed ethics board approval from the Vancouver Coastal Health Authority. MBI received initial ethics board approval in June 2005. As contemplated in the study protocol, Lion's Gate Hospital will provide to MBI blood and tumour tissue samples of confirmed lymphoma patients, and blood samples of confirmed leukemia patients.

August 1, 2006
Vancouver (August 1, 2006) - Lions Capital Corp, manager of BC Advantage Funds (VCC) Ltd. (FundSERV: BCA100) and Lions Liquidity Investment Fund I Limited Partnership, is pleased to announce today the closing of $7,550,000 of financing for Sirius Genomics Inc.

July 31, 2006
PRINCETON, N.J., July 31 -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced that J. Kevin Buchi, executive vice president and chief financial officer of Cephalon, Inc., has joined the Celator board of directors.

July 28, 2006
Vancouver, BC (July 28, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") announced today that representatives from the Company have requested a meeting with regulatory authorities to pursue the development of TTX. This step was outlined in WEX's strategic plan: if the in-depth analysis of the double-blind clinical trial data showed positive results, the Company would continue active development of the drug in cancer related pain.

July 27, 2006
VANCOUVER, CANADA - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that its Board of Directors has authorized management to proceed with an offer to purchase up to 13 million common shares in a modified "Dutch Auction" tender offer. If the offer is fully taken up it will represent approximately 15% of the currently outstanding shares for a maximum purchase price of approximately US$104 million.

July 27, 2006
VANCOUVER, CANADA - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the second quarter ended June 30, 2006. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

July 27, 2006
LANGLEY, BC, July 27 /CNW/ - AnorMED (TSX:AOM, AMEX:AOM) today released its financial results for Q1 Fiscal 2007 ended June 30, 2006 and provided an update on upcoming milestones based on the new strategic direction recently outlined by the Board.

July 26, 2006
VICTORIA, July 26 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV - News; TSX: ASV - News), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines for patients with less common diseases, today reported business and financial results for the second quarter ended June 30, 2006.

July 25, 2006
BURNABY, BC, July 25 - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce that the Company has engaged Evans & Evans, Inc., a financial advisory firm, to provide advice on financing and corporate development strategies.

July 24, 2006

Vancouver, Canada, July 24, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced interim clinical results from the 300mg dosing group for its Phase 2a pilot study of RSD1235 (oral). The safety data for this first of two dosing groups suggests that RSD1235 (oral) appears well-tolerated within the target population. The interim analysis further demonstrated a clear positive trend toward efficacy, with 61% (33 of 54) of patients receiving RSD1235 (oral) completing the study in normal heart rhythm, as compared to 37% (10 of 27) of patients receiving placebo.


July 24, 2006
VANCOUVER — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that results of a new preclinical study demonstrates that the Company’s proprietary compound NAP may help protect and aid recovery of newborn infants from brain injury caused by respiratory interruption. The study was published online this month in the Journal of Pharmacology and Experimental Therapeutics.

July 21, 2006
Vancouver, Canada, July 21, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a teleconference call and webcast will be held on Monday, July 24, 2006 at 9:00am EST (6:00am PST) to discuss interim results from the Phase 2a pilot study for RSD1235 (oral). A press release will be issued prior to the call.

July 20, 2006
VANCOUVER, July 20 - Protox(TM) Therapeutics Inc. (TSX-V:PRX) todayannounced that it has acquired a Phase II clinical stage program for thetreatment of cancer from Neurocrine Biosciences Inc. and the United StatesPublic Health Service (PHS).

July 20, 2006
VANCOUVER, July 20 /CNW/ - Chemokine Therapeutics Corp. (the "Company")(TSX:CTI; OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that the Company will present the blood vessel regeneration effects of its novel compound CTCE-0324 at the 2006 Gordon Research Conference on Chemotactic Cytokines to be held in Aussois, France during September 18-22, 2006.

July 20, 2006
VANCOUVER, July 20 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has signed an agreement with KMT Japan to sell Angiotech's Contour Threads(TM) product line in Japan, which is the ninth largest aesthetics market worldwide according to the International Society of Aesthetic Plastic Surgery (ISAPS). These top ten countries combined perform approximately 68% of all global aesthetic procedures.

July 19, 2006
VANCOUVER, July 19, 2006 - Protiva Biotherapeutics Inc. announced today that it intends to withhold its consent and pursue the law suit it filed against Inex Pharmaceuticals Corporation (INEX, TSX: IEX) in March 2006 to prevent an improper transfer of Protiva's agreements with Inex and other assets into a new company called Tekmira Pharmaceuticals Corporation.

July 19, 2006
VICTORIA, British Columbia, July 19, 2006 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation , reports that Mycophenolate Mofetil (MMF, CellCept(R)) has been approved for the treatment of lupus nephritis in Malaysia.

July 18, 2006

Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it anticipates completing the spin-out of the Company’s technology, products, cash and partnerships into Tekmira Pharmaceuticals Corporation (“Tekmira”) by the end of September 2006.


July 17, 2006
Vancouver, BC, Canada, July 17, 2006 - Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that at its recent Annual General Meeting, Dr. Alan Moore and Mr. Kevin McGarry have been added to its Board of Directors.

July 17, 2006
Cambridge, Mass., and Vancouver, BC – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Inex Pharmaceuticals Corporation (TSX: IEX), announced today that based on progress made to date, the companies are accelerating their collaboration focused on the systemic delivery of RNAi therapeutics.

July 17, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT’s Visudyne(R) (verteporfin) product of US$95.3 million for the quarter ended June 30, 2006. This represents a decrease of 26.1% over sales in the second quarter of 2005 and a 10.7% decline compared to the first quarter of 2006. Visudyne sales in the U.S. for the quarter were approximately US$18.9 million, representing 20% of total sales for the quarter.

July 17, 2006
PRINCETON, N.J., July 17 /PRNewswire/ -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced that it has received confirmation that the Examining Division of the European Patent Office intends to grant a European patent covering the company's proprietary CombiPlex(TM) technology. CombiPlex, the company's drug ratio technology platform, represents a unique approach in the development of combination chemotherapies to treat cancer.

July 13, 2006
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 07/13/2006 -- Protiva Biotherapeutics Inc., a development stage biotechnology company focused on the advancement of pharmaceutical products to fight serious human diseases such as cardiovascular disease and cancer, announced today the completion of a convertible debenture financing with commitments of CAD$5.6 million. This third round of financing brings Protiva's cumulative venture capital financing to CAD$26 million.

July 13, 2006
VANCOUVER, BC, and SAN DIEGO, CA, July 13 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three months and the year ended April 30, 2006 and an update on its programs:

July 12, 2006
BURNABY, BC, July 12 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce that it has closed its non-brokered private placement announced on April 4, 2006.

July 12, 2006
VANCOUVER, July 12, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the Company’s proprietary compound NAP has been shown in preclinical studies to be effective in reducing both amyloid plaques and neurofibrillary tangles in the brain, two pathologies most closely correlated with Alzheimer’s disease in humans.

July 11, 2006
VANCOUVER, July 11 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that its Chief Scientific Officer, Dr. Nathan Yoganathan, will be presenting at the Pediatric Oncology Experimental Therapeutics Investigation Consortium, or P.O.E.T.I.C., Conference being held July 19-21 in Banff, Alberta.

July 11, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it will revise its Plan of Arrangement for spinning out Tekmira Pharmaceuticals Corporation in order to further increase the value of the spinout for INEX shareholders and to fulfill a commitment made under a debt purchase and settlement agreement with the previous holders of certain convertible promissory notes.

July 11, 2006
BURNABY, BC, July 11 /CNW/ - Chromos Molecular Systems (TSX:CHR) announced today that it has achieved significant progress in the development of the ACE System, its proprietary technology platform for engineering cell lines for the manufacture of biopharmaceuticals including monoclonal antibodies (MAbs).

July 11, 2006
VICTORIA, July 11 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV - News; TSX: ASV - News), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today announced the appointment of Dr. Richard Jones as Senior Vice President (SVP) Clinical and Regulatory Affairs.

July 10, 2006
Vancouver, Canada, July 10, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced amendments to its co-development agreement with Astellas Pharma US, Inc., related to the planned re-submission of the New Drug Application (NDA) for RSD1235 (iv), an investigational new drug for acute conversion of atrial fibrillation.

July 10, 2006
VICTORIA, July 10 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines for patients with less common diseases, today announced preliminary revenues of approximately US$51 million for the second quarter of 2006, which includes the effect of a nominal reconciliation amount.

July 10, 2006
VANCOUVER, July 10 /CNW/ - AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that enrollment has been completed for one of two pivotal Phase III trials being conducted with MOZOBIL for stem cell transplant.

July 7, 2006

Vancouver, Canada, July 7, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that representatives from its co-development partner Astellas Pharma US, Inc. and Cardiome have met with the U.S. Food & Drug Administration (FDA) to discuss the “refusal to file” (RTF) letter received on May 30, 2006 for the New Drug Application (NDA) for RSD1235 (iv), an investigational new drug for the acute conversion of atrial fibrillation. 


July 6, 2006
VANCOUVER, BC and SAN DIEGO, CA, July 6 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Thursday, July 13th, 2006 at 4:15 p.m. ET (1:15 p.m. PT) to discuss financial results for the fourth quarter and the year ended April 30, 2006.

July 6, 2006
VANCOUVER, July 6 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Jeffrey P. Walker, MD as Senior Vice President, Research and Development.

July 6, 2006
Burnaby, British Columbia, Canada – Chromos Molecular Systems Inc. (TSX:CHR) today announced that Ron MacKenzie has been appointed to its Board of Directors.

July 6, 2006
Vancouver, BC (July 6, 2006) - WEX Pharmaceuticals Inc. (the "Company") is pleased to announce that the detailed analysis of the Phase IIb/III data collected during the double-blind, randomized, placebo controlled study of Tectin(TM) in inadequately controlled moderate to severe cancer pain is progressing.

July 6, 2006
BURNABY, BC, July 6 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V:WBI), is pleased to announce the recent appointment of Dr. Liren Tang as Chiefof Biology Department and Senior Cell Biologist.

July 5, 2006

VANCOUVER, July 5, 2006 — Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that results of a preclinical study published online on June 19th in the Journal of Neurochemistry extends the body of research demonstrating the mechanism by which the Company’s clinical stage products AL-108 and AL-208, protect and repair brain cells from disease or injury.


June 30, 2006
VANCOUVER, June 30 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that further to its letter of intent with the Ontario Institute for Cancer Research (OICR), MBI has received ethics board approval from the Ontario Cancer Research Ethics Board.

June 30, 2006
Vancouver, BC (June 30, 2006) - WEX Pharmaceuticals Inc. (the "Company") today
announced that Don Evans has given notice to resign from his position as Vice
President Corporate Communications of the Company.

June 28, 2006
VANCOUVER, June 28 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has completed its acquisition of privately held Quill Medical, Inc. ("Quill") - including all of its technology and intellectual property - for US $40 million in cash plus certain future contingent payments based on product revenues, as previously announced on May 25, 2006.

June 28, 2006
VANCOUVER, June 28 /CNW/ - iCo Therapeutics Inc. announced today that Dr. Jason Slakter will join its strategic advisory team. An internationally renowned retinal specialist, Dr. Slakter currently practices at the Vitreous-Retina-Macula Consultants in New York. He is a Clinical Professor of Ophthalmology at the New York University School of Medicine and an attending surgeon and Surgeon Director at the Manhattan Eye, Ear and Throat Hospital.

June 28, 2006
VANCOUVER, June 28 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the "Company") (TSX:CTI - News; OTCBB:CHKT - News), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced today that Guy Ely, M.D. has been appointed to serve as Chief Medical Officer, and will be responsible for overseeing Chemokine's overall clinical development program and regulatory filings.

June 27, 2006
RICHMOND, BC, June 27 /CNW/ - bioLytical(TM) Laboratories announced today, that their INSTI(TM) kit, a rapid HIV antibody test developed by the company, received CE Mark approval in their European Community.

June 26, 2006
VANCOUVER, B.C., CANADA and BURLINGAME, CA, U.S.A. – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) and BioSeek, Inc. announced today that they have entered into a research collaboration agreement. Under the collaboration, BioSeek, a leader in applying integrated human biology systems for developing new therapeutics, will apply its proprietary BioMAP® Systems in an effort to characterize the mechanisms of action of the LSAIDsTM, Inflazyme’s Leukocyte Selective Anti-inflammatory Drugs, which make up Inflazyme’s respiratory program. Inflazyme Pharmaceuticals is a biopharmaceutical company focused on respiratory and inflammatory diseases. Financial terms of the agreement were not disclosed.

June 26, 2006
Celator Pharmacueticals Appoints Industry Veteran Felix Botelho as Head of Commercial Development. Company Also Expands Office and Research Facilities at Headquarters in Princeton, NJ and at Research Center in Vancouver, BC to Accommodate Expanding Development Program in Combination Chemotherapeutics.

June 26, 2006
Victoria, B.C. June 26, 2006 - GenoLogics Life Sciences Software Inc. (GenoLogics), a leading developer of lab and management software solutions for proteomics biomarker discovery and research, today announced a data and workflow management solution for Genomics researchers. Geneus™, will be based on an open, configurable, integrating platform, and purposed for genomics and systems biology researchers.

June 23, 2006

Protox Therapeutics Inc. (TSX-V:PRX) today announced that it has retained The Equicom Group Inc. to provide the Company with strategic investor relations and financial communications services.


June 23, 2006
VANCOUVER, June 23 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that it has signed a letter of intent with the Ontario Institute for Cancer Research (OICR) pursuant to which the Ontario Tumour Bank, an initiative of the OICR, will provide to MBI tumour tissue samples of confirmed lymphoma patients. Such samples may also include normal adjacent tissue and/or buffy coat samples.

June 22, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it will be exhibiting at the Institute of Food Technologists (IFT) Annual Meeting and Food Expo at the Orlando Convention Center (booth #3176) in Orlando, Florida from June 24-28, to showcase a number of Reducol™-based products.

June 22, 2006
VANCOUVER June 22, 2006 - Officials from the University of British Columbia and the University of California have announced that a growing partnership between California and Canadian research leaders has resulted in the completion of a new ultra-high bandwidth connection between Canada's national research and education network and the California state education network. The partnership has also defined four areas of research collaboration for further investigation.

June 21, 2006
CANTEST Ltd. unveiled today details of its $9.5 Million expansion plan, which includes the redesign and occupancy of a nearby building as well as the expansion of its current head office.

June 21, 2006
EDMONTON, June 21 /CNW/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Proteon Therapeutics, Inc, of Waltham, Massachusetts and Kansas City, Missouri, announced today the signing of a contract for process development and manufacturing of PRT-201, Proteon's lead drug candidate.

June 20, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it has signed an agreement with Fayrefield Foods Ltd. (Fayrefield) of Crewe, UK, to establish a new UK company for the purpose of expanding distribution of finished products containing Forbes’ cholesterol-lowering ingredient, Reducol™.

June 20, 2006
VANCOUVER, CANADA (June 20, 2006) – Perceptronix Medical Inc. (“Perceptronix”), a
Vancouver based cancer diagnostics company, announced today that it has recently raised
CDN$5.5 M in private financing designed to serve as a bridge to an anticipated larger
institutional private placement financing.

June 20, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has signed a definitive note purchase and settlement agreement with all of the holders (the “Noteholders”) of certain convertible promissory notes (the “Notes) issued by a wholly-owned subsidiary of INEX and guaranteed by INEX.

June 20, 2006
SAN DIEGO, CA, June 20 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today that the European Patent Office has granted two patents to Nventa related to HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases. HspE7 consists of a heat shock protein (Hsp) covalently fused to an HPV E7 viral protein to form one CoVal(TM) therapeutic protein.

June 19, 2006
Monday, June 19, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced that at its annual general meeting held today in Vancouver, shareholders elected the following members to its board of directors: Frank Holler (Chairman), Dr. Avtar Dhillon, Jim Heppel, Nitin Kaushal, Dr. Fahar Merchant, Dr. James Miller and Dr. Donald Rix.

June 15, 2006

Thursday, June 15, 2006 – Vancouver, British Columbia – Protox Therapeutics Inc. (TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox’s President and Chief Executive Officer, will be a featured presenter at the Sachs Associates 2nd Annual London Biotech Investment Forum to be held June 22, 2006 at the London Stock Exchange.


June 15, 2006
VANCOUVER/SAN DIEGO, June 15 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has completed enrollment in a Phase IIb study of celgosivir (MX-3253) in combination with PEG-INTRON(R) (peginterferon alfa-2b), and PEGETRON(TM) (peginterferon alfa-2b plus ribavirin) for the treatment of hepatitis C virus (HCV) infection in genotype 1 patients who were non-responders or partial responders to previous treatment with pegylated interferon-based therapy.

June 15, 2006
SAN DIEGO, CA, June 15 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or dysplasia, in HIV-positive individuals.

June 15, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the Netherlands’s largest retailer, Albert Heijn, has launched a range of cholesterol-lowering dairy products incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™. The product range, marketed under the Albert Heijn private label brand, will include: a margarine spread, a spoonable yogurt, and ‘original’ and ‘strawberry flavor’ yogurt drinks.

 

June 14, 2006
Wednesday, June 14, 2006 – Vancouver, British Columbia – Protox Therapeutics Inc. (TSX-V: PRX) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office entitled “Modified Protein Toxins and Use Thereof for Treating Disease”. The patent application provides added protection for drug candidates generated through the PORxin™ platform whose binding sites are altered to target certain types of cells including cancer cells.

June 14, 2006
VANCOUVER, June 14 /CNW/ - iCo Therapeutics Inc. announced today that Dr. Philip Rosenfeld has joined iCo's strategic advisory team. Dr. Rosenfeld is Professor of Ophthalmology at the world-renowned Bascom Palmer Eye Institute at the University of Miami, Miller School of Medicine.

June 14, 2006
BURNABY, BC, June 14 /CNW/ - Chromos Molecular Systems Inc. ("Chromos"; TSX: CHR) announced today the appointment of Mr. Jeff Charpentier, CA as the Company's Vice President, Finance and Chief Financial Officer.

June 13, 2006

Vancouver, Canada, June 13, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the appointment of Curtis Sikorsky, CA to the position of Chief Financial Officer. Mr. Sikorsky, a chartered accountant since 1996, brings over ten years of public and private company experience as well as three years of direct audit and tax experience with a major audit firm.


June 13, 2006
VICTORIA, June 13 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV - News; TSX: ASV - News), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today announced that William Hunter, MD, MSc has been appointed to the Company's Board of Directors.

June 13, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has appointed Dr. Ian John Massey, to its board of directors.

June 13, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the completion of enrollment for the US Phase II trial of its cholesterol-lowering compound, FM-VP4. To date, there have not been any significant safety issues or concerns raised during the trial’s progress.

June 13, 2006
LANGLEY, BC, June 13 /CNW/ - AnorMED (TSX:AOM, AMEX:AOM) today released its financial results for the fiscal year ended March 31, 2006 and issued a statement providing a current outlook for the next 12 months and beyond based on the new strategic direction for the Company.

June 12, 2006
Vancouver, BC (June 12, 2006) -WEX Pharmaceuticals Inc. ("WEX" or the "Company") is pleased to announce that it has received approval for its IND (Investigational New Drug) application with the US FDA (Food and Drug Administration) to initiate a clinical trial of Tectin™. This represents a significant achievement since for the first time, WEX will perform a trial under a US-IND number, and this will grant access to a major patient population base for future TTX development.

June 9, 2006
VANCOUVER, June 9 /CNW/ - AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that the Company will participate at the Needham Biotechnology Conference in New York City. Bill Adams, CFO, will present at the conference being held at the New York Palace Hotel on Thursday, June 15 at 3:30pm EDT. A live webcast of the presentation will be available on AnorMED's website at www.anormed.com.

June 9, 2006
Wednesday, June 7, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox's President and Chief Executive Officer, will be a featured presenter at the 2006 Fasken Martineau Technology and Life Sciences Forum to be held June 13, 2006 at the Hyatt Regency Vancouver in British Columbia.

June 8, 2006
VANCOUVER, June 8 /CNW/ - AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that the Company will participate at the Pacific Growth Equities Healthcare Conference in San Francisco.

June 7, 2006
SAN DIEGO, CA, June 7 /CNW/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa. The patent covers compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins.

June 7, 2006
MEDIA RELEASE | JUNE 7, 2006 - New therapies for stroke patients may soon be possible, thanks to a discovery made by a team of University of British Columbia neuroscience researchers who have found a new stroke death channel - the conduit through which key chemicals are lost from brain cells during stroke, causing the cell death that disables stroke victims.

June 6, 2006
Victoria, B.C June 06, 2006 - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and Roche (OTC: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for CellCept® (mycophenolate mofetil) in the treatment of pemphigus vulgaris (PV). Aspreva is currently evaluating CellCept for the treatment of PV in a global phase 3 study.

June 5, 2006
VANCOUVER, June 5 /CNW/ - Med BioGene Inc. ("MBI") (TSX Venture: MBI) is pleased to announce the appointment of Bruce Cousins, C.A., as a director of MBI.

June 5, 2006
VANCOUVER, June 5 /CNW/ - iCo Therapeutics announced today the appointment of Dr. Richard W. Barker and William Jarosz to its board of directors.

June 2, 2006
VANCOUVER, June 2 /CNW/ - Carolyn Cross (the "Offeror"), President and Chief Executive Officer of Ondine Biopharma Corporation, has purchased an aggregate of 523,250 common shares in the capital of Ondine Biopharma Corporation ("Ondine"), representing approximately 1.1% of the issued and outstanding share capital of Ondine as at June 1, 2006. Of the common shares acquired, 420,000 were acquired in the market through the facilities of the TSX and the balance in private transactions.

June 2, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 2, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, is pleased to announce its participation in the 2006 Fasken Martineau Technology and Life Sciences Forum to be held June 13th, 2006 at the Hyatt Regency.Gordon McCauley, President and CEO of Allon, will be presenting at 1:45 p.m. providing a corporate overview and update on clinical development of Allon's neuroprotective product candidates.

June 2, 2006
VANCOUVER, June 2 /CNW/ - AnorMED Inc. (TSX: AOM, AMEX: AOM) announced today the departure of Elisabeth Whiting, the Company's Vice President of Communications, effective immediately. This decision followed an assessment of overall management requirements by the new Chair and Interim CEO, Kenneth Galbraith.

June 1, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it will present at Pacific Growth Equities’ Life Sciences Growth Conference on Tuesday, June 13, 2006 at 10:00 a.m. at the InterContinental Mark Hopkins Hotel in San Francisco.  Dr. Kevin Mullane, President and CEO of Inflazyme, will provide a business overview and discuss the Company’s product pipeline.

June 1, 2006
SAN DIEGO, CA, June 1 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB) announced today that it has changed its name to Nventa Biopharmaceuticals Corporation (TSX: NVN). Nventa common shares are expected to begin trading under a new Toronto Stock Exchange symbol 'NVN' on June 7, 2006. The Company's new website is located at www.nventacorp.com.

May 31, 2006

Vancouver, Canada, May 31, 2006 -- Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM) today announced that its co-development partner, Astellas Pharma US, Inc., has received a “refusal to file” letter from the U.S. Food & Drug Administration for the New Drug Application (NDA) for RSD1235 (iv), an investigational new drug for the acute conversion of atrial fibrillation.


May 30, 2006
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Canaccord Adams Life Sciences Mini-Conference in Montreal on Wednesday, May 31, 2006 at 2:30pm EST (11:30am PST).

May 30, 2006

Vancouver, Canada, May 30, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a teleconference call and webcast to discuss corporate developments will be held on Wednesday, May 31, 2006 at 8:45am EST (5:45am PST).


May 30, 2006
VANCOUVER, May 30 /CNW/ - Med Biogene Inc. (TSX-V - MBI) today reported its financial results for the quarter ending March 31, 2006.

May 29, 2006
Protox Therapeutics Inc. (TSX-V: PRX) announced today the release of its financial statements for the three months ending March 31, 2006 and provided an update on company progress.

May 26, 2006
Perceptronix Medical Inc. (“Perceptronix”) announces receipt of CE Mark for its ClearSign™ Sputum Test for the detection of early lung cancer, allowing it to be marketed in the European Union.

May 25, 2006
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) announced it will hold its annual analyst and investor meeting today in New York City, where it will be providing information with respect to its business, clinical programs and financial plans

May 25, 2006
Creating Further Opportunities in Aesthetics and Wound Closure Markets.  Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it has entered into a definitive agreement to acquire privately held Quill Medical, Inc. ("Quill"), a provider of specialized, minimally invasive aesthetic surgery and wound closure technology, for US $40 million in cash, plus certain future contingent payments based on product revenues.

May 25, 2006
MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, has issued its 18th CEO Message from Jim DeMesa, MD, President & CEO.

May 25, 2006
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that Peter J. O’Callaghan will be joining QLT as Senior Vice President, Corporate Development and General Counsel.

May 25, 2006
Chemokine Therapeutics Corp. (the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has closed a previously announced transaction with Pharmaceutical Product Development, Inc. ("PPD") and re- acquired its licensing rights on its compound CTCE-0214. PPD will retain an interest in the CTCE-0214 program through potential future milestone payments.

May 24, 2006
The Board of Directors of AnorMED Inc. (TSX:AOM, AMEX:AOM) today announced that Dr. Mike Abrams has stepped down as President and Chief Executive Officer, effective immediately.

May 24, 2006
3 students from all across BC won 1 platinum, 3 gold, 6 silver, 7 bronze, 6 honorable mentions and 10 special awards, as well as $54,200 in awards and scholarships at this year's Canada-Wide Science Fair, held in Saguenay, Quebec, May 13-21, 2006.

May 24, 2006
Today Clera Inc. announced the appointment of Jeanne M. Bertonis as President and Chief Operating Officer and Jeffrey A. Bacha as Executive Vice President, Corporate Affairs and Chief Financial Officer. Bertonis and Bacha will join the company officially in these roles in July 2006.

May 23, 2006
GenoLogics Life Sciences Software Inc. (GenoLogics), the leading provider of lab and data management solutions for proteomic and systems biology research, and Bioinformatics Solutions Inc.

May 23, 2006

May 23, 2006
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced
today that it will delay the initiation of its Phase IIa Atrigel/octreotide
program in acromegaly patients. This decision was made, in cooperation with
the U.S. Food and Drug Administration (FDA), following adverse event findings
that occurred in an ongoing primate toxicology study designed to support
repeated injections in patients.

May 23, 2006

May 23, 2006
VANCOUVER, B.C., CANADA - Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today reported its financial results for the fourth quarter and year ended March 31, 2006.

May 22, 2006
Urigen Holdings Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications and Kalium Inc., a California-based boutique drug development company, today announced that Urigen has licensed Kalium's patents and technology for the use of suppositories to deliver drug therapies to treat diseases of the genitourinary tract.

May 19, 2006
Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced that at today’s hearing in the British Columbia Court of Appeal the Court unanimously ruled in favour of INEX.

May 19, 2006
Med BioGene Inc. ("MBI") (TSX Venture: MBI) is pleased to announce the appointment of Erinn B. Broshko as Chief Executive Officer and a director of MBI.

May 19, 2006
Dr. Don Rix, Chairman of the Board of CANTEST Ltd., was welcomed yesterday into The Business Laureates of BC Hall of Fame.

May 18, 2006
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it will delay the initiation of its Phase IIa Atrigel/octreotide program in acromegaly patients.

May 17, 2006
Cardiome Pharma Corp. would like to congratulate everyone who participated in the Vancouver Sun Run this year. In total, 28 teams from the BC Biotech membership participated in the run. Team rankings were determined by the sum of positions of the first 10 people across the finish line for each team.

May 17, 2006
TAXUS benefits demonstrated in non-diabetic patient population carry over into insulin-treated diabetic patients

May 16, 2006

May 16, 2006
Ondine Biopharma Corporation (the "Company", TSX/AIM: OBP) today announced that it has signed a comprehensive, multi-year research and development agreement with UCL Biomedica Plc to develop additional applications to prevent and treat infectious diseases using Photodynamic Disinfection (PDD) technology.

May 16, 2006
MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has received a Notice of Authorization from Health Canada to begin a Phase II viral kinetics study of MX-3253 (celgosivir) in hepatitis C virus (HCV) infected, treatment-naive patients.

May 16, 2006
Boston Scientific's second-generation stent system now approved for treatment of acute mycocardial infarction, total occlusions and in-stent restenosis Large vessel TAXUS Liberté stent also receives CE mark

May 16, 2006
Boston Scientific's second generation stent compares favorably to market leading TAXUS Express(2)(TM) stent system, even with more complex lesions

May 16, 2006
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced that its corporate partner Boston Scientific Corporation ("BSC") has announced three-year follow-up data from its TAXUS VI clinical trial.

May 15, 2006

Vancouver, Canada, May 15, 2006 - Cardiome Pharma Corp. (NASDAQ: CRME / COM: TSX) today reported financial results for the first quarter ended March 31, 2006. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). At close of business on March 31, 2006, the exchange rate was CAD$1.00 = U.S. $0.8562.


May 12, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the UK’s second largest retailer, Wal-Mart /ASDA, has launched Heartfelt Plus Natural Cheese incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™. Heartfelt Plus is the first cheddar cheese in the UK to combine both low-fat and cholesterol-lowering benefits. The product is expected to be on store shelves Thursday, May 11th.


May 12, 2006
Welichem Biotech Inc. (the "Company") (TSX-V: WBI), is pleased to announce that the Company's board of directors approved on May 8, 2006 a grant of incentive stock options to directors, officers, employees and consultants of the Company for the purchase of a total of 1,950,000 common shares of the Company at a price of $0.10 each until May 7, 2011.

May 11, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced that the results of the Phase IIa study of IPL512,602 in patients with mild-moderate persistent asthma will be presented at the 2006 American Thoracic Society (ATS) International Conference being held May 19-24, 2006 in San Diego, California. The title of the presentation is: The Effect of IPL512,602 in Patients with Mild-Moderate Persistent Asthma (NEAT Study).

May 11, 2006
Vancouver, Canada, May 11, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monaco on Tuesday, May 16, 2006 at 10:30am local time (4:30am EST).

May 11, 2006
Stressgen Biotechnologies Corporation (TSX: SSB) announced today financial results for the first quarter ended March 31, 2006. All amounts, unless specified otherwise, are in Canadian dollars.

May 11, 2006
Research by a 16-year-old Ottawa-area student that contributes new insights into the workings of the HIV-AIDS virus has earned top prize in the 2006 National sanofi-aventis biotech challenge, announced today in a ceremony at the National Research Council.

May 11, 2006
Vancouver, Canada, May 11, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report 2006 first quarter financial results on the afternoon of Monday, May 15, 2006. Cardiome will hold a teleconference call and webcast at 4:30pm EST (1:30pm PST) on that day to discuss the results.

May 9, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced the start of the Phase IIb study with IPL512,602 in patients suffering from moderate to severe asthma. The study known as the Control of Asthma Patients Symptomatic on Inhaled Corticosteroids Study (CAPSICS), is an eight week, randomized, double blind, parallel group, multi-center trial comparing the efficacy of IPL512,602 to placebo.

May 9, 2006
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) and Genzyme Corporation (NASDAQ: GENZ) today announced that they have entered into a strategic collaboration agreement designed to identify, develop and commercialize innovative therapies for cancer patients undergoing surgical removal of tumors.

May 9, 2006
Angiotech Pharmaceuticals, Inc. announces results for the first quarter of 2006

May 9, 2006
Chemokine Therapeutics Corp. (the Company) , a biotechnology company developing drugs in the field of chemokines, today announced that the Company's President and Chief Executive Officer, Dr. Hassan Salari, will be a featured presenter at the upcoming Rodman & Renshaw Third Annual Global Healthcare Conference in Monte Carlo, Monaco.

May 9, 2006
Aspreva Pharmaceuticals Corporation today announced that Richard Glickman, Chairman & CEO, will be presenting at the Banc of America Health Care Conference in Las Vegas.

May 8, 2006
Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has closed the previously announced transaction to license three products from its Targeted Chemotherapy pipeline to Hana Biosciences, Inc. (“Hana”; Nasdaq: HNAB). INEX has granted Hana a worldwide license to develop and commercialize Marqibo™ (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan).

May 8, 2006
BC Biotech’s Volunteer of the Year Award is presented to an individual in recognition of volunteer contributions made to BC Biotech, the biotech industry, and community. Dale Gann’s involvement with BC Biotech began approximately three years ago at the BIO 2003 International Conference in Washington DC, when he recognized the opportunity to improve British Columbia’s presence at the conference in comparison to our international competitors.

May 8, 2006
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that the Toronto Stock Exchange has accepted notice of QLT’s intention to make a normal course issuer bid in the open market through the facilities of the Toronto Stock Exchange and/or the NASDAQ Stock Market.

May 8, 2006
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the promotion of Doug Janzen to the position of President and Chief Business Officer. Mr. Janzen for three years prior to this appointment has been Cardiome’s Chief Financial Officer.

May 5, 2006

Med BioGene Inc. (“MBI”) (TSX Venture: MBI) is pleased to announce that on Friday, April 28, 2006, MBI completed its acquisition of Dragon-Tex (Group) Limited (“DTX”) (TSX Venture: DTX). As part of the acquisition, the shareholders of DTX exchanged their common shares for common shares of MBI on the basis of two common shares of DTX for one common share of MBI.


May 5, 2006
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported additional results, including QT data, from a Phase 1 study for RSD1235 (oral) for the prevention of recurrence of atrial fibrillation. Initial results from this study were announced in a press release dated August 31, 2005.

May 4, 2006
VANCOUVER, May 4 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical- stage developer of drugs for infectious and degenerative diseases, has raised $8.8 million through the sale of a partial royalty interest (the "Royalty Conversion Units") to US-based investment funds.

May 4, 2006
Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, today announced it is the recipient of the 2006 British Columbia Biotechnology Award for Life Sciences Company of the Year.

May 3, 2006

OncoGenex Technologies Inc. today announced encouraging results from a Phase I study evaluating systemic administration of OGX-011 in combination with standard chemotherapy agents, gemcitabine and cisplatin, in patients with non-small cell lung cancer (NSCLC). The one-year survival rate for the nine patients that received at least one dose of OGX‑011 in combination with chemotherapy was 67 percent. All but one of the nine patients showed either a partial response defined by a greater than or equal to 30 percent tumor size reduction, or stable disease defined by less than 30 percent tumor size reduction. Of the 55 percent of patients reported as stable disease, tumor reduction ranged from 10.3 percent to 29.7 percent. While patient evaluation is still ongoing, the median time for follow-up is 12.7 months (range 11.8 to 16.6 months) and the median time for survival has not yet been reached. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc. (NASDAQ:ISIS).


May 3, 2006

Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) reported today as part of its first quarter 2006 financial results continued progress towards completing the spin-off of its Targeted Immunotherapy platform and product candidates into a new public company and completing a partnering transaction for its Targeted Chemotherapy products.


May 3, 2006
Natick, MA and Vancouver, BC (May 3, 2006) -- Boston Scientific Corporation (NYSE: BSX) and Angiotech Pharmaceuticals, Inc (NASDAQ: ANPI, TSX: ANP) announced today that they received a favorable decision from a Dutch court in a patent dispute against Sahajanand Medical Technologies Pvt. Ltd. Boston Scientific andAngiotech alleged that Sahajanand's Infinnium paclitaxel-elutingstent infringed two claims of an Angiotech patent directed topaclitaxel stents. The Court found that the asserted claims were infringed and valid.

May 2, 2006
Chemokine Therapeutics Corp. (the Company) (TSX: CTI; OTCBB: CHKT), a biotechnology company developing drugs in the fieldof chemokines, today announced that it has started patient dosing in a phaseIb/II clinical trial using CTCE-9908, the Company's lead anti-cancer product.

May 2, 2006
The Vancouver Island Technology Park (VITP), aninitiative of the University of Victoria today announced the expansion ofAspreva Pharmaceuticals' global headquarters.

May 2, 2006
Protox Therapeutics Inc. (TSX-V: PRX) today announced the enrollment and successful dosing of the first patient in a Phase I clinical study evaluating their lead drug, PRX302, to treat localized recurrent prostate cancer. PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 destroys the cells by punching holes in the cell membrane.

May 2, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 2, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, has presented a case study during IBC's "TIDES 2006: Oligonucleotide and Peptide Technology and Product Development" in Carlsbad, California. This pre-clinical study confirmed that Allon's drug candidates penetrate the blood brain barrier, have a well-understood bioavailability and reach their target therapeutic areas in the central nervous system. It also showed that the intranasal administration of AL-108 and the intravenous administration of AL-208 appeared rapidly in the plasma, cerebrospinal fluid and the brain.

May 1, 2006
Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that on Friday April 28, 2006, INEX and certain of its directors and officers filed Statements of Defence in response to a claim filed by Protiva Biotherapeutics Inc. (“Protiva”) in the Supreme Court of British Columbia. INEX also filed a Counterclaim against Protiva. These legal filings can be accessed on the INEX website at www.inexpharm.com.

May 1, 2006
MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has added AnnKatrin Petersen, M.D. to its management team. Dr. Petersen, a highly experienced industry executive, has joined the company as Vice President of Clinical Development and will lead the Company's clinical development programs.

May 1, 2006
Ondine Biopharma Corporation ("the Company", TSX: OBP; AIM: OBP) today announced the appointment of Mr. Michael Richard Crane to its Board of Directors. Mr. Crane is an accomplished Senior Executive who is experienced in the Dental/Medical high-tech equipment and consumables industry.

April 27, 2006
Welichem Biotech Inc. (the "Company")(TSX-V: WBI), is pleased to announce that further to its news release datedApril 4, 2006 announcing the arrangement of a non-brokered private placementof up to 60,000,000 Units, that Canadian Maple Leaf Investment Co. Ltd. hasagreed to subscribe for 30,000,000 Units and as a result will become acontrolling shareholder, holding approximately 37.89% of the issued andoutstanding shares of the Company, on a fully diluted basis, upon completionof the private placement.

April 25, 2006
GenoLogics Life Sciences Software Inc. (GenoLogics) today announced that Fred Hutchinson Cancer Research Center chose Proteus™, GenoLogics’ proteomics purposed lab and data management solution, to use in its cancer biomarker discovery research in early detection of ovarian cancer. GenoLogics worked with the Hutchinson Center to integrate Proteus with the Center’s recently released Computational Proteomics Analysis System (CPAS) data repository.

April 25, 2006
WEX Pharmaceuticals Inc. ("WEX" or the "Company") is pleased to announce that Bill Chen, MSc., MBA,CPA has been named Chief Financial Officer. Trevor Sinclair has resigned from the position as the interim Chief Financial Officer.

April 24, 2006
QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of approximately US$106.8 million for the quarter ended March 31, 2006. This represents a decrease of 13.7% over sales in the first quarter of 2005.

April 21, 2006
VANCOUVER, April 21 /CNW/ - Shareholders of AnorMED Inc. (TSX:AOM, AMEX:AOM) today voted overwhelmingly to elect a new, independent and experienced Board of Directors to work for the benefit of all shareholders.

April 21, 2006
VANCOUVER, April 21 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) announced today that it has established Ondine Biopharma (U.S.A.) Inc., a wholly-owned subsidiary of Ondine Biopharma Corporation. Ms. Jacqueline Walker, a former Dentsply International executive, has been appointed President of this new subsidiary and will lead global commercialization efforts of Periowave(TM) as well as other applications of Ondine's innovative photodynamic disinfection technology.

April 20, 2006
Vancouver, BC, Canada, April 20, 2006 - Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that it has appointed Christina Yip as its Chief Financial Officer (“CFO”). Ms. Yip joins Pacgen from Cardiome Pharma Corp. (“Cardiome”), where she served as Vice President of Finance and Administration and Assistant Corporate Secretary to the Board. During her 8 year tenure at Cardiome, Ms. Yip progressed from Controller to Vice President of Finance and Administration and was integrally involved in various corporate finance activities including TSX listing, NASDAQ listing, acquisition of two US life sciences companies, and various public and private financings. She is filling the CFO role previously held by Mr. Fred Huang, MBA, who has been promoted to Senior Vice President and Chief Operating Officer of Pacgen. “We are extremely pleased to have Christina Yip joining us as our new CFO”, said David J. Cheng, Ph.D., President and CEO of Pacgen. He added, “we feel that we have significantly strengthened our management structure with the addition of Ms. Yip and the experience she brings with her from Cardiome.”

April 19, 2006
SAN DIEGO, CA, April 19 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB) today provided a corporate update and details regarding the next phase of clinical development of HspE7, a novel investigational therapeutic vaccine for the treatment of serious human papillomavirus (HPV)-related diseases. The Company had originally planned to begin a Phase III study in the first quarter of this year with the original HspE7 formulation. However, the Company announced that it will now be focusing its resources on the development of a more potent, reformulated version of HspE7.

April 19, 2006

Vancouver, Canada, April 19, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at two upcoming investor conferences.


April 18, 2006
SAN DIEGO, CA, April 18 /CNW/ - Stressgen Biotechnologies Corporation (TSX: SSB) announced today that the Company has hired Peter Emtage, Ph.D., as its Vice President of Research & Development. Dr. Emtage most recently led the research, development and technical operations at Biomira Inc.

April 13, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 13, 2006) - EnWave Corporation (TSX VENTURE:ENW) ("EnWave" or "the Company") is pleased to announce that it has reorganized its operations as part of an ongoing effort to focus business development energies on the biotechnology and food sectors.

April 12, 2006
Vancouver, BC, Canada, April 12, 2006 - Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that it has entered into an agreement with Western Life Sciences Venture Fund LP (“Western Life Sciences”) to acquire IL Therapeutics Inc. Western Life Sciences owned all of the outstanding shares of IL Therapeutics Inc. The purchase price included Pacgen preferred shares, common shares and common share purchase warrants. The assets of IL Therapeutics Inc. consist of CDN $1,500,000 and an early-stage drug technology, PAC-G31P.

April 12, 2006
VANCOUVER, April 12 /CNW/ - AnorMED Inc. (TSX: AOM; AMEX:AOM) announces that the Special Committee of AnorMED Board Rejects Compromise Slate of 7 Members.  AnorMED announces that its Special Committee of the Board of Directors, has resolved not to accept the proposal for a compromise in the proxy contest made by Dr. Michael Abrams, AnorMED's Chief Executive Officer, and which was accepted by Dr. Felix Baker, on behalf of the dissident shareholders.

April 12, 2006
VICTORIA, April 12 /CNW/ - Aspreva Pharmaceuticals Corporation (NASDAQ:ASPV; TSX: ASV), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, announced today that the company will release financial andbusiness results for the first quarter ending March 31, 2006 on Wednesday, April 26th. The Company will hold a conference call and webcast beginning at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these results.

April 12, 2006
VANCOUVER, BC, and CONSHOHOCKEN, PA, April 12 /CNW/ - NeuromedPharmaceuticals, a biopharmaceutical company developing next-generationchronic pain drugs, announced today that it has been named to FierceBiotech'sannual Fierce 15 list of top biotech companies to watch. This distinction,which was announced during the annual BIO meeting in Chicago, recognizesNeuromed as one of the top emerging biotech companies in 2006.

April 11, 2006
Vancouver, Canada - April 11, 2006 - Xenon Pharmaceuticals Inc., a privately held company engaged in developing small molecule therapies for select neurological, cardiovascular and metabolic diseases, today announced the completion of an equity financing of US$31 million. This investment will support the clinical development of Xenon’s product pipeline.

April 10, 2006
Dr. Stephen Arneric Named Vice President of Research and Preclinical Development. VANCOUVER, BC and CONSHOHOCKEN, PA, April 10 /CNW/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generationchronic pain drugs, today announced the appointment of Dr. Stephen Arneric toits executive team.

April 9, 2006
VANCOUVER, April 9 /CNW/ - AnorMED Inc. (TSX: AOM; AMEX:AOM) announces that The Baker Group has refused AnorMED's proposal to agree on a balanced 'hybrid' slate of directors.

April 7, 2006
VANCOUVER, April 7 /CNW/ - AnorMED Inc. (TSX: AOM; AMEX:AOM) announces that it is seeking a settlement with the dissident shareholders, represented by The Baker Group, involving agreement on the previously negotiated slate of directors comprised of five nominees from each slate and by submitting other outstanding issues to a third party mediator for resolution.

April 7, 2006
VANCOUVER, BC and TORINO, Italy, April 7 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced positive results from its Adhibit(TM) Adhesion Prevention Gel Myomectomy Study. The final data set was presented today by Dr. Lilo Mettler, the study's principal investigator, at the 19th Annual European Congress of Obstetrics and Gynecology in Torino, Italy.

April 6, 2006
Vancouver, B.C. - AnorMED Inc. (TSX: AOM; AMEX:AOM) announces that it has filed a Petition with the Supreme Court of British Columbia, asking that a group of dissident shareholders led by Baker Bros. Advisors LLC, be ordered to correct a misstatement published in their proxy circular. Baker Bros. is seeking to replace the AnorMED board of directors with its own slate of directors.

April 6, 2006

April 6, 2006
BURNABY, BC, April 6 /CNW/ - Chromos Molecular Systems Inc. ("Chromos" - TSX:CHR), a public biopharmaceutical company, has signed a contract with AppTec Laboratory Services, Inc. ("AppTec") for scale-up and manufacture of its monoclonal antibody drug product candidate CHR-1103. Chromos has used its proprietary ACE System to engineer cell lines for CHR-1103; AppTec will scale up and manufacture CHR-1103 for use in preclinical toxicology studies and Phase I clinical trials.

April 5, 2006
CANTEST Ltd. announced today the acquisition of Elemental Research Inc. (“ERI”), a highly-specialized, North Vancouver-based laboratory, which primarily services the pharmaceutical market.

April 5, 2006
In light of CANTEST’s recent acquisition of Elemental Research Inc. (“ERI”), the company is pleased to announce a number of additions and changes to its Management Team.

April 5, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has entered into an exclusive worldwide co-development and licensing agreement with Retinagenix, LLC, to develop active synthetic retinoid products for the treatment of degenerative retinal diseases.

April 5, 2006
VANCOUVER, April 5 /CNW/ - AnorMED Inc. (TSX: AOM; AMEX:AOM) announces today that a proxy circular filed by a group of dissident shareholders, represented by Felix J. Baker and seeking to replace the AnorMED Board of Directors, includes extensive criticism of decisions which Felix Baker, himself, approved as a Director of the Company since April 2004.

April 5, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today the decision of the U.S. Court of Appeals for the Federal Circuit to stay the injunction against the manufacture and sale of QLT USA Inc.'s Eligard(R) products that was entered on February 27, 2006, by the U.S. District Court for the Northern District of Illinois Eastern Division.

April 5, 2006
(Victoria, British Columbia, Canada) Hope is on the horizon for early detection of ovarian cancer thanks to a $1 million (CAD) donation to the BC Cancer Foundation from Canary Foundation, a U.S. non-profit organization dedicated to funding early detection of cancer.

April 4, 2006
VANCOUVER, CANADA (April 4, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been issued a Medical Device Listing from the US Food and Drug Administration (FDA) and CE Mark for its Clear2C™ Quantitative DNA Staining Kit. Perceptronix will now begin marketing and selling this product to all laboratories requiring consistent quantitative absorbance microscopy staining in the United States, Canada, and the European Union (EU) .

April 4, 2006
BURNABY, BC, April 4 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), is pleased to announce that it has arranged a non-brokered
private placement of up to 60,000,000 Units at a purchase price of $0.075 per
unit, for total gross proceeds of up to $4,500,000.

April 3, 2006
Vancouver, Canada—Protox Therapeutics Inc. (TSX-V: PRX) announced today that preclinical data demonstrating PRX302’s validity as a treatment for prostate cancer and benign prostatic hyperplasia (BPH) is being presented in a poster session at the 97th Meeting of the American Association of Cancer Research (AACR), which is being held this week at the Washington Convention Centre in Washington, D.C.

April 3, 2006
BURNABY, BC, April 3 /CNW/ - Chromos Molecular Systems Inc. (TSX: CHR), apublic biopharmaceutical company, today announced its fiscal results for thefiscal year ended December 31, 2005.

March 31, 2006

QSV Biologics (QSV), Ltd. Edmonton, Alberta, Canada, announced today that they have signed a contract with a biomedical company, Tissue Therapies Limited (ASX: TIS) for the process development and cGMP manufacture of clinical quantities of some of the therapeutic protein components of the VitroGro® platform for the accelerated healing of burns. cGMP means Current Good Manufacturing Practices - the quality level of production required for human treatment.


March 31, 2006

March 31, 2006
VANCOUVER, March 31 /CNW/ - AnorMED Inc. (AMEX:AOM; TSX:AOM) todayannounced that the Company will participate at the Annual CIBC World MarketsHealthcare Conference in New York City. Michael Abrams, President & CEO, willpresent at the conference being held at the Millennium Broadway Hotel in NewYork on Tuesday, April 4 at 3:45pm EST. Live webcasts of the presentation willbe available on AnorMED's website at www.anormed.com.

March 31, 2006
Vancouver, Canada, March 31, 2006 - Cardiome Pharma Corp. (NASDAQ: CRME / COM: TSX) today reported financial results for the fourth quarter and year ended December 31, 2005. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

March 31, 2006

Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced Astellas’ submission of a New Drug Application (NDA) to the United States Food & Drug Administration (FDA) seeking approval to market the intravenous formulation of RSD1235, an investigational new drug for the acute conversion of atrial fibrillation.


March 30, 2006
VANCOUVER, CANADA (March 30, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today the opening of its first Quantitative Cytology Laboratory in Vancouver, British Columbia.

March 30, 2006
Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the year ended December 31, 2005 versus the year ended December 31, 2004. All amounts are in Canadian dollars unless otherwise noted. Fiscal Year 2005 Highlights · Reported total revenue of $21 million for year ended December 31, 2005 versus $17.6 million for year ended December 31, 2004, a 19% increase

March 30, 2006

VANCOUVER, BC - Inex Pharmaceuticals Corporation ("INEX"; TSE: IEX) announced today as part of its 2005 audited operating results that it expects the two corporate strategic initiatives it launched in 2005 with the intention of maximizing stakeholder value for all Company assets will be achieved during 2006.


March 30, 2006
VANCOUVER, March 30 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;AIM: OBP) today announced CE Mark approval for its proprietary Periowave(TM)Photodynamic Disinfection (PDD) System for the treatment of periodontaldiseases. This regulatory milestone clears the way for Ondine to beginpreparations for marketing its advanced, laser-based antimicrobial systemthroughout the EU as well as selected countries throughout the world."CE Mark approval permits us to expand our market reach beyond Canada,where Periowave(TM) is currently being sold," said Carolyn Cross, Presidentand CEO of Ondine Biopharma. "The CE Mark also indicates that we have met theessential health, safety and environmental protection requirements detailed inthe European Directives covering medical devices."


March 30, 2006
VANCOUVER, March 30 /CNW/ - Inex Pharmaceuticals Corporation("INEX"; TSX: IEX) announced today as part of its 2005 audited operatingresults that it expects the two corporate strategic initiatives it launched in2005 with the intention of maximizing stakeholder value for all Company assetswill be achieved during 2006.


March 30, 2006
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York at 10:30am EST (7:30am PST) on Tuesday, April 4, 2006.

March 29, 2006

VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has received a statement of claim filed by Protiva Biotherapeutics Inc. (“Protiva”) in the Supreme Court of British Columbia. Protiva, a private biotechnology company, was spun-out from INEX in 2001 along with certain intellectual property rights relating to gene therapy technology. INEX holds a minority interest in Protiva.


March 29, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it would release its financial results for the year ended December 31, 2005 after market on Thursday, March 30, 2006. A conference call and webcast to discuss these financial results will be held on Thursday, March 30, 2006 at 1:30pm PT. (4:30pm ET)


March 29, 2006
Abgenix announces stockholder approval of acquisition by Amgen.

March 29, 2006
VANCOUVER, March 29 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the execution of a development, license and distribution agreement between its wholly-owned subsidiary, Surgical Specialties Corporation (SSC), and Collagen Matrix Technologies Inc. (CMT), appointing SSC to be the exclusive worldwide distributor of CMT's

March 29, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 29, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today its 2005 audited operating results. The Company made significant progress in 2005 - and year-to-date in 2006 - toward achieving its goal to develop drugs that halt or prevent serious degenerative diseases and injury to the central nervous system.

March 29, 2006
Vancouver, Canada, March 29, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will hold a teleconference call and webcast at 11:00am EST (8:00am PST) on Friday, March 31, 2006 to discuss year-end and fourth-quarter 2005 financial results and provide an update on clinical advancements.

March 28, 2006

VANCOUVER, BRITISH COLUMBIA – Protiva Biotherapeutics announced today it has filed two lawsuits to protect its right to continue advancing the research and development of delivery technologies that are crucial to a new class of drugs that could help prevent and treat a wide variety of diseases.


March 27, 2006
Vancouver, B.C. – The Board of Directors of AnorMED Inc. (TSX: AOM; AMEX:AOM) has recommended that shareholders vote in favor of the AnorMED slate of director nominees and reject any slate of director nominees that may be proposed by a dissident group of shareholders, represented by The Baker Group, holding approximately 23 percent of the Company’s shares.

March 27, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has signed an exclusive research collaboration agreement with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) to evaluate Alnylam’s RNAi therapeutics with INEX’s systemic liposomal delivery technology.

March 27, 2006
Vancouver, BC (March 27, 2006) -WEX Pharmaceuticals Inc. ("WEX" or the "Company") is pleased to announce that it has received the results of an inspection of its manufacturing plant in China.

March 27, 2006
VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 27, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has begun dosing its first patient for a Phase Ib human clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company's second product AL-208 as a treatment for neurodegenerative indications where multiple doses are required.

March 27, 2006
Vancouver, Canada—CEO Clips, a series of two minute corporate profiles on Canadian companies, will feature Protox Therapeutics Inc. (TSX-V: PRX) on The Biography Channel beginning March 27, 2006 at various times throughout the day and evening. It will also be posted on Yahoo Finance Canada and can be viewed online at www.protoxtherapeutics.com .

March 24, 2006
VICTORIA, BC, and SAN DIEGO, CA, March 24 /CNW/ - Stressgen
Biotechnologies Corporation (TSX:SSB) ("Stressgen") announced today that the
corporate reorganization involving Stressgen and 0747036 B.C. Ltd.
("Investor"), an affiliate of Madison Group, a diversified investment firm,
has been completed. The transaction was previously announced on January 30,
2006, and securityholder approval for the transaction was announced on
March 16, 2006.

March 23, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced its revenue outlook for Reducol™ and other cholesterol-lowering ingredients. The Company forecasts strong growth in Reducol™ sales and other value added products for 2006 with anticipated revenue of $6.0 – 6.5 million compared to the approximate $3.9 million in 2005, up to a 67% increase. Including anticipated licensing and interest income, the total revenue guidance for 2006 is $7 - 7.5 million. The anticipated growth in revenue is primarily based on contracted and forecasted amounts for Reducol™ for sale into the functional food and dietary supplement markets.


March 23, 2006
VANCOUVER, British Columbia, March 23 /CNW/ -- Angiotech Pharmaceuticals (Nasdaq: ANPI, TSX: ANP) today announced that it has closed the previously announced acquisition of American Medical Instruments Holdings, Inc. (AMI), a leading independent manufacturer of specialty, single-use medical devices, for approximately CDN $900 million in cash subject to post-closing adjustments. The transaction, which was announced on February 1, 2006, provides Angiotech with global manufacturing, marketing, and sales capabilities and enhances the Company's ability to capitalize on its current product pipeline in a wide range of specialty therapeutic areas. The acquisition of AMI also significantly diversifies Angiotech's revenue base.

March 22, 2006
SAN DIEGO, CA, March 22 /CNW/ - Stressgen Biotechnologies Corporation (TSX: SSB) announced today financial results for the year ended December 31, 2005. All amounts, unless specified otherwise, are in Canadian dollars.

March 21, 2006
Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics) announced today a cutting edge development resulting from its strategic partnership with the Institute for Systems Biology (ISB), an internationally known research institute with a mission of exploring the complexities of human genes in order to prevent and treat diseases. Through collaborative development efforts, it is now possible for the ISB’s Trans Proteomic Pipeline (TPP), a set of free, open-source programs developed with support from the National Heart, Lung and Blood Institute that run in series to form a ‘pipeline’, to be seamlessly launched from GenoLogics Proteus™ lab and data management system for proteomics. This new development was demonstrated by GenoLogics at the US HUPO conference in Boston . Proteus is the only data management solution on the market with this capability.

March 21, 2006
A University of British Columbia Chemistry researcher and creator of one of the world's most successful eye disease treatments has been awarded the 2005 Gerhard Herzberg Canada Gold Medal for Science and Engineering, widely recognized as the country's most prestigious science award.

March 21, 2006
Vancouver, Canada, March 21, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Bear Stearns Biotech West Coast Confab in San Francisco at 4:00pm PST (7:00pm EST) on Thursday, March 23, 2006.

March 20, 2006
VANCOUVER, BC and WHITEHOUSE STATION, NJ, March 20 /CNW/ - Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced today that they havesigned a research collaboration and license agreement to research, develop andcommercialize novel compounds for the treatment of pain and other neurologicaldisorders, including Neuromed's lead compound, NMED-160, which is currently inPhase II development for the treatment of pain.

March 20, 2006
Vancouver, B.C. – AnorMED Inc. (AOM:TSX; AOM:AMEX) provides shareholders with additional information regarding AnorMED’s decision to reschedule the Special meeting of shareholders given that no consensual resolution regarding the requisition to replace the existing Board of Directors could be achieved.

March 17, 2006

VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it has signed a Letter of Intent to license three products from its Targeted Chemotherapy pipeline to Hana Biosciences, Inc. (“Hana”; AMEX: HBX). INEX has granted Hana a worldwide license to develop and commercialize Marqibo™ (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan). The two companies expect to close the transaction in the second quarter of 2006 after the completion of legal agreements.


March 17, 2006
VANCOUVER, March 17 /CNW/ - AnorMED Inc. (TSX:AOM, AMEX:AOM) announced today that negotiations with the requistionists have been terminated and the Company expects to mail out its proxy circular the week of March 27, 2006.

March 16, 2006
VICTORIA and SAN DIEGO, CA, March 16 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB) ("Stressgen") announced today that the corporate reorganization involving Stressgen and 0747036 B.C. Ltd. ("Investor"), an affiliate of Madison Group, a diversified investment firm, has been approved by Stressgen's securityholders. The transaction was previously announced on
January 30, 2006.

March 16, 2006

Vancouver, Canada – Protox Therapeutics Inc. (TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox’s Chief Executive Officer, will present at the Invest Northwest 2006 CEO and Investor Forum to be held March 21 and 22, 2006 at the Bell Harbor International Conference Center in Seattle, Washington.


March 16, 2006
VANCOUVER, March 16 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI;TSX:ANP) (the "Company") today announced that it has priced the offering of US $250 million in aggregate principal amount of 7.75% senior subordinatednotes due 2014. The offering is being made in a private placement, and theclosing of the offering is conditioned on the satisfaction of customaryconditions, the concurrent closing of a new senior secured credit facility andthe consummation of the acquisition of American Medical Instruments Holdings,Inc. ("AMI"). The notes will be guaranteed on a senior subordinated basis bycertain of Angiotech's direct and indirect subsidiaries.

March 15, 2006
VANCOUVER, March 15 /CNW/ - Angiotech Pharmaceuticals, Inc.

(NASDAQ: ANPI; TSX: ANP) was advised yesterday by the Federal Trade Commission that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") has terminated, allowing Angiotech to proceed with the previously announced acquisition of privately-held American Medical Instruments Holdings, Inc. (AMI), subject to the satisfaction of the remaining closing conditions.


March 14, 2006
CANTEST is pleased to announce the appointment of Humphrey Tebit to head up its newly created Biopharmaceutics Department.

March 14, 2006
VANCOUVER, March 12 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI: TSX:ANP) today announced that its corporate partner Boston Scientific
Corporation ("BSC") today welcomed results from the independent, multi-center STENT registry, the largest prospective, comparative real world drug-eluting stent study ever reported.

March 14, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the completion of the sale of its interest in Phyto-Source, the Company's 50-50 sterol manufacturing joint venture, for US$25 million to Chusei Oil Co. Ltd., the Japanese parent company of the Company's former joint venture partner, Chusei (U.S.A.) Inc. Forbes has received the US$25 million under the agreement, announced February 23, 2006. Forbes has also received the remaining US$1 million of its original US$4 million loan to Phyto-Source. Additionally, all guarantees provided by Forbes USA to Phyto-Source's lenders for the joint venture's commercial term loan, line of credit and capital equipment lease have been discharged.

March 14, 2006
VANCOUVER, March 14 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI; TSX: ANP) today announced that its corporate partner Boston Scientific Corporation ("BSC") has announced preliminary six-month results from its ARRIVE II registry, confirming the safety of the TAXUS(R) Express(2)(TM) coronary stent system in "real-world" patients.

March 13, 2006
Vancouver, B.C. – AnorMED Inc. (TSX:AOM, AMEX:AOM) announced today that the upcoming special shareholder meeting has been postponed from April 11, 2006 and is now scheduled for April 18, 2006 in Vancouver. The record date of the special shareholder meeting, February 28, 2006, remains the same.

March 9, 2006

Vancouver, Canada, March 9, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that an abstract for the RSD1235 IV ACT 3 trial will be presented at the American College of Cardiology (ACC) Scientific Sessions 2006, taking place in Atlanta, Georgia from March 11-14, 2006.


March 8, 2006
VANCOUVER, BC and CONSHOHOCKEN, PA, March 8 /CNW/ - Neuromed
Pharmaceuticals, a biopharmaceutical company developing next-generation
chronic pain drugs, today announced the completion of a Series D financing of
US$25 million. This fourth round of financing brings Neuromed's cumulative
venture capital financing to US$74 million.

March 8, 2006
VANCOUVER, March 8 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI;
TSX: ANP) today announced that its corporate partner Boston Scientific
Corporation ("BSC") has submitted to the U.S. Food and Drug Administration
(FDA) the final module of BSC's Pre-Market Approval (PMA) application for its
TAXUS(R) Liberté(TM) paclitaxel-eluting coronary stent system.

March 8, 2006
VANCOUVER, BC and SAN DIEGO, CA, March 8 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three and nine months ended January 31, 2006 and an update on its programs.

March 8, 2006
VANCOUVER, March 8 /CNW/ - Ondine Biopharma Corporation (TSX:OBP; AIM:OBP) ("Ondine") today announced the commercial availability of its first Photodynamic Disinfection product, PERIOWAVE(TM), at the Pacific Dental Conference being held in Vancouver, Canada on March 9-11th, 2006. Ondine has received a Class II Medical Device License from Health Canada to market PERIOWAVE(TM) for the treatment of chronic periodontitis, a disease affecting approximately 50% of the population over the age of 50.

March 7, 2006

March 7, 2006
Vancouver, BC, Canada, March 7, 2006 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that it has received approval from the Institutional Review Board (IRB) at the University of Southern California in Los Angeles to conduct a Phase I/II clinical study of PAC-113 mouthrinse for the treatment of oral candidiasis in HIV seropositive individuals.  The clinical study may begin immediately.  The study protocol was submitted to the active Investigational New Drug Application (IND) with the United States Food and Drug Administration (US FDA) in early November 2005.

March 7, 2006

VANCOUVER, March 7 /CNW/ - Angiotech Pharmaceuticals, Inc.(NASDAQ: ANPI; TSX: ANP) corporate partner Boston Scientific Corporation ("BSC") today announced the schedule of BSC's major events at the annual American College of Cardiology Scientific Session, which runs from March 11 to 14 in Atlanta, Georgia.


March 7, 2006
We are pleased to announce that ASKA Research is the official Canadian provider of educational products by The RAN Institute, as well as high-quality online professional development courses.

March 6, 2006
VANCOUVER, March 7 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) ("Ondine") announced today its financial results for the year and fourth quarter ended December 31, 2005.

March 6, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that the Court of Appeal has informed QLT USA, Inc. that the injunction against promoting, manufacturing, selling and offering for sale Eligard(R) has been stayed pending its decision to grant a permanent stay of the injunction.

March 2, 2006
VANCOUVER, March 2 /CNW/ - iCo Therapeutics Inc. announced today that Dr. Alan Bird has joined iCo's Strategic Advisory Team. A pioneer in ophthalmic research, teaching and clinical medicine, Dr. Bird's contributions to the field of retinal disease have met with worldwide acclaim.

March 2, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) together with Helicon Therapeutics, Inc. of New York, today announced the initiation of a Phase IIa clinical study with the PDE4 inhibitor, IPL455,903 (also known as HT-0712) in subjects with Age Associated Memory Impairment. IPL455,903 is a PDE4 inhibitor licensed to Helicon Therapeutics that has shown to be safe, well tolerated and non-emetic in healthy volunteers in single and multi-dose studies conducted to date.

March 2, 2006

March 2, 2006

March 1, 2006
CANTEST Ltd. today announced that it has acquired controlling interest in Prime Trials, Inc., a Vancouver-based, privately-operated Contract Research Organization (CRO) specializing in Phase I and IIa clinical trials.

February 28, 2006
VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it intends to pursue an appeal from the recent Supreme Court of British Columbia ruling providing the holders of INEX’s outstanding convertible promissory notes the right to vote on INEX’s Plan of Arrangement to spin-out its Targeted Immunotherapy assets into a new company, Tekmira Pharmaceuticals Corporation (“Tekmira”).  The ruling was received February 13, 2006 and the original hearing took place January 5 and 6, 2006.  

February 28, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced UK’s largest retailer, Tesco Stores Ltd (Tesco), has started selling a milk drink incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™. The milk drink is marketed under the Tesco private label brand.


February 27, 2006
VANCOUVER, Feb. 27 /CNW/ - Mr. David Scott, Chairman of the Special Committee of the board of directors of AnorMED Inc. (TSX:AOM, AMEX:AOM) has responded to a letter from Felix J. Baker contained in a filing of a further amendment, made February 23, 2006, to a Schedule 13D filing with the United States Securities and Exchange Commission by Felix J. Baker and Julian C. Baker.

February 27, 2006
VANCOUVER, Feb. 27 /CNW/ - Dr. Michael Abrams, CEO of AnorMED Inc. (AOM: TSX, AOM:AMEX), announced that he has exercised previously granted options to purchase 350,000 common shares of AnorMED.

February 27, 2006
VANCOUVER, CANADA--The Board of Directors for QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that it has appointed Robert Butchofsky as President and Chief Executive Officer and as a Director of the Board. The Board also named C. Boyd Clarke as the new Chairman. Both of these appointments are effective immediately. Past Chairman E. Duff Scott will remain as a Director of the Board.

February 27, 2006
VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced it’s intention to appeal the decision of the U.S. District Court for the Northern District of Illinois Eastern Division (the "Court"), issued late today, granting an injunction enjoining QLT, Sanofi-aventis and their subsidiaries from promoting, manufacturing, selling and offering for sale QLT USA, Inc.’s Eligard(R) product in the United States until May 1, 2006.

February 24, 2006

VANCOUVER, BC, Feb 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced that it intends to appeal a UK trial court decision to revoke Angiotech's UK designation of its European Patent No. 0,706,376. The UK trial court ruled today that Angiotech's UK Patent lacked inventive step in light of certain prior art in a challenge brought by Conor MedSystems (Conor) filed in February 2005. This Patent, which applies to the UK only, is only one of a number in Angiotech's portfolio of patents protecting its pioneering paclitaxel stent technology, which cover the Boston Scientific TAXUS™ stent.


February 23, 2006
VANCOUVER, Feb. 23 /CNW/ - Chemokine Therapeutics Corp. (the Company) (TSX: CTI; OTCBB: CHKT), a biotechnology company developing drugs in the field of chemokines, today announced that the 97th Annual Meeting of the American Association for Cancer Research in 2006 has accepted the results of the research study of Chemokine Therapeutics' Anti-Cancer compound, CTCE-9908, in a model of prostate cancer for presentation.

February 23, 2006
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced it has agreed to sell its interest in Phyto-Source LP, the Company’s 50-50 sterol manufacturing joint venture, for US$25 million to Chusei Oil Co. Ltd., the Japanese parent company of the Company’s joint venture partner, Chusei (U.S.A.) Inc. Simultaneously, Phyto-Source and Forbes Medi-Tech signed a supply agreement which will assure Forbes Medi-Tech of a supply of Reducol™ and other wood sterols for a period of 5 years.  Forbes has agreed to buy all of its sterol requirements exclusively from Phyto-Source for the first year.  


February 22, 2006

VANCOUVER, CANADA--QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported its financial results for the fourth quarter ended December 31, 2005 and full year 2005 as well as issued its Visudyne sales guidance for 2006. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.


February 21, 2006
February 21, 2006 – Vancouver, BC - Ventures West, one of Canada’s largest private venture capital companies, is pleased to announce that Dr. Mohammad Azab has joined the firm as Entrepreneur in Residence.   Dr. Azab, former Executive Vice President of Research and Development and Chief Medical Officer of QLT Inc., will be involved in identifying and evaluating investment opportunities in the biotech sector.

February 21, 2006

VANCOUVER, Feb. 21 /CNW/ - AnorMED Inc. (TSX:AOM, AMEX:AOM) is pleased to announce that Michael Abrams, President and CEO, is the recipient of the Society of Chemical Industry's (SCI) 2006 Julia Levy Award recognizing successful innovation in Canada in the field of bio-medical science and engineering.


February 21, 2006

February 20, 2006

CANTEST announced today that it will contribute $250,000 towards research on the effects of chemical substances in the Environment on the health of Aboriginal people in Northern BC.


February 16, 2006

VANCOUVER, Feb 16, 2006 /PRNewswire-FirstCall via COMTEX/ Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it has filed notification with the U.S. Department of Justice and the Federal Trade Commission of its intention to acquire privately held American Medical Instruments Holdings, Inc. (AMI), in compliance with the pre-merger notification requirements of the Hart-Scott- Rodino Antitrust Improvements Act of 1976. AMI also filed its notification today.


February 15, 2006
VANCOUVER, Feb. 15 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP) corporate partner, Boston Scientific ("BSC") announced today that it has received reimbursement approval from the French government for its TAXUS(R) Liberté(TM) paclitaxel-eluting coronary stent system - the world's first next-generation drug-eluting stent system. The announcement was published yesterday in the official journal of the French government, "Journal Officiel de la République Française."

February 15, 2006

VANCOUVER, Feb. 15 /CNW/ - iCo Therapeutics Inc. announced today that it has selected Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) to manufacture and supply iCo 007. Under terms of the agreement, Isis will produce a sufficient quantity of iCo 007 for use in all Phase I and II studies.


February 14, 2006

February 14, 2006

February 14, 2006
VANCOUVER, British Columbia, Canada February 14, 2006 – OncoGenex Technologies Inc., announced the appointment of Mr. Stephen Anderson as Chief Financial Officer and Mr. Tom Bailey as a member of the Board of Directors of OncoGenex. 


February 13, 2006

Vancouver, British Columbia – Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced it has extended its supply and licensing contract with Pharmavite LLC until mid 2007 for the continued sale of Reducol™, the branded cholesterol lowering ingredient in one of Pharmavite’s leading dietary supplements, Nature Made® CholestOff®.


February 13, 2006
VANCOUVER, B.C., CANADA - Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced its third quarter financial results for the period ended December 31, 2005.

February 13, 2006
Vancouver, BC (February 13, 2006) – Chemokine Therapeutics Corp. (the Company) (OTCBB: CHKT; TSX: CTI), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that it has entered into a Material Transfer Agreement (MTA) with researchers at the National Cancer Institute (NCI) in Bethesda, MD, to supply NCI with Chemokine Therapeutics’ CTCE-9908.

February 10, 2006

Vancouver, BC – Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ:FMTI) announced today that Charles Butt, President and CEO of Forbes, is scheduled to present at the BIO CEO & Investor Conference 2006 on Wednesday, February 15, 2006 at 8:30a.m. Eastern Time (5:30a.m. Pacific Time.) The presentation will take place in the Duke of Windsor Room at the Waldorf Astoria Hotel at 301 Park Avenue, New York, New York.


February 9, 2006
MISSISSAUGA, ON, Feb. 9 /CNW/ - AstraZeneca Canada Inc. demonstrated its
continued commitment to improving the health of British Columbians, as
President and CEO Mike Cloutier announced three investments in the province
totalling $4.6 million.

February 9, 2006
Vancouver, BC (February 9th, 2006) –Chemokine Therapeutics Corp. (the Company) (OTCBB: CHKT; TSX: CTI), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that Dr. Mohammad Azab, QLT Inc’s former Chief Medical Officer and Executive Vice President of Research and Development, has joined Chemokine Therapeutics’ Board of Directors.

February 8, 2006
VANCOUVER, CANADA (February 8, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been issued Medical Device Licenses from Health Canada for its first two products – the ClearCyte™ Quantitative Cytology System and its associated Clear2C™ Quantitative DNA Staining Kit. Perceptronix can now market these two products in Canada.

February 8, 2006

Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today reported business and financial results for the fourth quarter and full-year ended December 31, 2005. Fourth quarter revenues were $45.0 million with earnings of $0.68 per fully diluted share. Full year revenues were $76.5 million with earnings of $0.62 per fully diluted share. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.


February 7, 2006
VANCOUVER, Feb. 7 /CNW/ - AnorMED Inc. (AMEX:AOM, TSX:AOM) today reported financial results for its third fiscal quarter ended December 31, 2005. AnorMED recorded a net loss of $11,403,000 ($0.34 per common share) in this quarter. This is in comparison to the net loss incurred in the previous fiscal quarter ended September 30, 2005 of $9,255,000 ($0.29 per common share).

February 6, 2006
Vancouver, BC (February 6, 2006) – Chemokine Therapeutics Corp. (the Company) (TSX: CTI; OTCBB: CHKT), a biotechnology company developing drugs in the field of chemokines, today announced that it has received approval from Health Canada to initiate a phase Ib/II clinical trial using CTCE-9908, a chemokine CXCR4 antagonist.

February 6, 2006
Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics) announced today that Scripps  Florida, a division of The Scripps Research Institute, has selected GenoLogics solutions for its lab and scientific data management system for proteomics and systems biology research.

February 3, 2006

Burnaby, British Columbia. Inspired leadership, impressive growth and industry-leading business practices helped CANTEST Ltd. emerge from thousands of applicants to earn a spot amongst the 50 Best Managed Companies in Canada.


February 2, 2006
VANCOUVER, CANADA (February 2, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has received CE Mark for its first product – the ClearCyte™ quantitative pathology system, allowing it to be marketed throughout the European Union (EU).

February 2, 2006

Burnaby, British Columbia, Canada, Chromos Molecular Systems Inc. (TSX:CHR) announced that it has acquired Targeted Molecules Corporation (TMC), a privately held biotechnology company based in San Diego, CA.  With the acquisition, Chromos gains two antibody product candidates for treatment of multiple sclerosis (MS) and acute thrombosis.  Concurrent with the acquisition, Chromos completed a Cdn. $6 million financing, the funds from which will be used to finance operations.


February 2, 2006
Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics), the leading provider of an integrating platform and data management systems for systems biology research is pleased to announce the appointment of Don Listwin to the company’s board of directors.  

February 2, 2006

February 1, 2006
VANCOUVER, Feb. 1 /CNW/ - Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI, TSX: ANP) today announced that it has entered into a definitive agreement to acquire privately held American Medical Instruments Holdings, Inc. (AMI), a leading independent manufacturer of specialty, single-use medical devices, for approximately CDN $900 million in cash.

January 30, 2006
VANCOUVER, Jan. 30 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) This morning Singapore based Biosensors International Group announced that "it has successfully defended against legal claims and defeated a request for an injunction request brought against it in the court in the The Hague by Vancouver, BC-based Angiotech Pharmaceuticals, Inc. and Boston Scientific Corporation" and, "The Judge ruled that Biosensors Axxion DES does not infringe the European Patent."

January 30, 2006
SAN DIEGO, CA, Jan. 30 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB) ("Stressgen" or the "Company") announced today that it has entered into an agreement with 0747036 B.C. Ltd. ("Investor"), an affiliate of Madison Group, a diversified investment firm, to recapitalize and reorganize Stressgen's business, resulting in non-dilutive funding totaling up to $9.25 million.

January 27, 2006

VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced that at its Special Meeting of Shareholders held yesterday, shareholders of INEX approved the Plan of Arrangement to complete the spin-out of INEX’s Targeted Immunotherapy assets into a new company, Tekmira Pharmaceuticals Corporation ("Tekmira") with 98.3% of shares cast voting in favour of the spin-out. Shareholders also approved a stock option plan for Tekmira.


January 26, 2006

VANCOUVER, Jan. 26 /CNW/ - AnorMED Inc. (TSX:AOM, AMEX:AOM) advises that it has now received a requisition to convene a special meeting of shareholders for the purposes of replacing the existing Board of Directors from various entities controlled by Felix J. Baker and Julian C. Baker. Felix Baker is a Director of AnorMED Inc. This requisition was received subsequent to the Company's News Release of January 17, 2006.


January 23, 2006

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced the extension of a major sterol supply agreement for a minimum of US$4.8 million between Forbes’ manufacturing joint venture, Phyto-Source LP, and a large multinational company. The contract was originally signed in September 2002, renewed in June 2004 and under the latest extension is effective until the end of 2006. For competitive reasons, the identity of the customer and contractual terms and conditions have not been disclosed.


January 23, 2006
VANCOUVER, CANADA (January 23, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today the initiation of the Coventry site to their clinical study for the ClearVu Elite™ fluorescence endoscopy system for the early detection of lung cancer, raising the total trial sites to four, including; St. Petersburg, Russia; Ljubljana, Slovenia and Vancouver, Canada.

January 23, 2006
VANCOUVER, BC and SAN DIEGO, CA, Jan. 23 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, released the Company's 17th CEO Message today. The CEO Message provides an overview of the MX-3253 and CPI-226 clinical programs for 2006 and the first half of 2007, including the Company's plan to initiate a combination therapy viral kinetics clinical trial of celgosivir (MX-3253) in Hepatitis C virus (HCV) patients.

January 17, 2006

VANCOUVER, Jan. 17 /CNW/ - AnorMED Inc. (TSX:AOM, AMEX:AOM) announces that Felix J. Baker and Julian C. Baker have filed a report with the U.S. Securities and Exchange Commission disclosing the intention of various entities controlled by them to requisition a special meeting of AnorMED shareholders for the purposes of replacing the Board of Directors with a new slate proposed by them. Felix Baker is a Director of AnorMED Inc.


January 17, 2006
Jim Heppell and David Raffa, the principals of Catalyst Corporate Finance Lawyers, and Fasken Martineau DuMoulin LLP, are pleased to announce that Fasken Martineau will be acquiring Jim and David's law practice effective February 1, 2006.

January 16, 2006
Protox Therapeutics Inc. announced today that the Investigational New Drug (IND) application for PRX302, the Company’s lead product for the treatment of recurrent localized prostate cancer, has been cleared by the US Food and Drug Administration (FDA).

January 10, 2006
Burnaby, British Columbia. CANTEST Ltd. is pleased to announce the acquisition, installation and validation of two API 5000 LC-MS/MS™ systems, worth together over $1.5 million. The state-of-the-art machines, the first installation of their kind in Western Canada, support pharmaceutical development from drug discovery through clinical trials and will be used within the company’s BioPharma Services division at the CANTEST Life Sciences Centre near Vancouver, British Columbia.

January 9, 2006
Burnaby, British Columbia, Canada, Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR), announced today that it has expanded the scope of its collaboration agreement with Pfizer.  Under the expanded agreement, Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate.  The parties will also initiate a collaborative program to genetically engineer production cell lines.

January 5, 2006
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced the appointment of Louis Drapeau as a Director of Inflazyme and Chairman of its Audit Committee.  Graham Wilson, previously Chairman of Inflazyme’s Audit Committee, has resigned from the Board of Directors.

January 4, 2006

 

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced UK’s largest retailer, Tesco Stores Ltd (Tesco), will start selling a range of products including a margarine spread, yogurt, and yogurt drink incorporating Forbes Medi-Tech’s cholesterol-lowering ingredient, Reducol™ sometime next week. The products will be marketed under the Tesco private label brand.

 


January 3, 2006
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has filed an information circular with securities regulators in Canada relating to the transaction announced on November 17, 2005 to spin-out its Targeted Immunotherapy technology and products into a new public company.  The shareholder meeting to approve the transaction will take place January 26, 2006 and the transaction is expected to close March 1, 2006.